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GLOSSARY 
ALS  Amyotrophic Lateral Sclerosis 
cap  7-methyl-guanosine 
CTD  Carboxy-terminal domain 
dsRNABD double-stranded RNAs Binding Domain 
FALS  Familiar Amyotrophic Lateral Sclerosis 
FUS/TLS Fused in sarcoma/translocated in liposarcoma 
hnRNP heterogeneous nuclear ribonucleoproteins 
miRNA microRNA 
MN  motoneuron 
MRE  microRNA Response Element 
NES  Nuclear Export Signal 
NII  Neuronal Intranuclear Inclusions 
NLS  Nuclear Localization Signal 
NMD  nonsense-mediated mRNA decay 
QGSY  Gln-Gly-Ser-Tyr-rich region 
RGG  Arg-Gly-Gly-rich motif 
RNAPII RNA polymerase II 
RNAPIII RNA polymerase III 
ROS  Reactive oxygen species 
RRM  RNA recognition motif 
SALS  Sporadic Amyotrophic Lateral Sclerosis 
snRNA small nuclear RNAs 
snRNP  small nuclear ribonucleoprotein 
SOD1  Superoxide dismutase 1 
SR protein serine/arginine-rich protein 
TAF15 TATA-binding protein associated factor 15 
TBP  TATA binding protein 
TDP43 TAR DNA-binding protein 43 
TFIID  Transcription Factor II D 
TUTase Terminal Uridil Transferases 
UTR  untranslated region  
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SUMMARY 
FUS is a multifunctional protein involved in almost all step of RNA 
metabolism, from transcription, to splicing and RNA transport and 
translation. FUS mutations have been associated to Amyotrophic 
Lateral Sclerosis (ALS) onset, a lethal neurodegenerative disease 
that leads to specific degeneration of upper and lower motoneurons. 
In this research project I demonstrated that FUS is involved in 
microRNA (miRNAs) biogenesis, a family of small RNAs that 
participate in post-transcriptional regulation of gene expression by 
repressing mRNA translation. In particular I demonstrated that FUS 
is important for the biogenesis of a group of miRNAs, including 
those with a pivotal role in neuronal differentiation and 
synaptogenesis. I showed that FUS is able to participate in miRNAs 
biogenesis facilitating the processing of precursor molecules (pri-
miRNAs). Furthermore, I demonstrated that FUS is able to activate 
two feed-forward regulatory loops important for the maintenance of 
the correct cellular level of the FUS protein. Increased amount of 
FUS has been described, indeed, in ALS patients, suggesting that 
the overdose of FUS becomes toxic for the cellular homeostasis. In 
particular, a strong increase of FUS protein has been described in 
ALS patients carrying mutations in the 3’UTR of FUS mRNA. 
Even though, in this case, the protein is wild type, an ALS 
phenotype still occurs, and this may be due to the failure of some 
regulatory mechanisms that control FUS levels. I showed the 
existence of two mechanisms able to control FUS levels: on one 
side FUS induces the skipping of the exon 7 of its own pre-mRNA, 
leading to the formation of an out-of-frame mRNA predicted to be 
degraded by nonsense-mediated decay; on the other side FUS is 
able to upregulate miR-141 and miR-200a, which in turn repress 
FUS synthesis. Therefore when FUS levels increase, these two 
feed-forward regulatory loops, acting on pre-mRNA splicing and on 
mRNA translation, are able to restore the physiological levels of 
FUS. The failure of these mechanisms might contribute to the ALS 
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pathogenesis, where the uncontrolled increase of FUS results toxic 
for the cell. Notably, one mutation found in the 3’UTR of FUS in 
two ALS patients, is localized in the binding site for miR-141 and 
miR-200a, and I demonstrated that this mutation affects the ability 
of these miRNAs to target FUS mRNA. So, in these patients, this 
regulatory process probably fails in controlling FUS protein levels, 
and this may be one of the mechanisms leading to ALS 
pathogenesis.  
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1 – INTRODUCTION 
1.1 - Amyotrophic Lateral Sclerosis 
Amyotrophic Lateral Sclerosis (ALS) is a devastating late-onset 
disorder that leads to specific degeneration of upper and lower 
motor neurons. Loss of these neurons leads to muscle atrophy, 
weakness, fasciculations and spasticity.  
The age of clinical onset of ALS is variable, but the majority of the 
patients develop the disease after the fourth decade of life; juvenile 
ALS forms also exist, but are less common (Robberecht et al., 
2013). Most patients with ALS die within 3 to 5 years after 
symptoms onset due to respiratory insufficiency, but the variability 
in clinical disease duration is large and ranges from months to 
decades (Logroscino et al., 2008). Large differences in survival and 
age of onset are a hallmark of this disease, even between patients 
carrying the same mutation and belonging to the same family, 
suggesting the presence of other factors that influence the 
phenotype (Regal et al., 2006). Large differences exist also in the 
incidence of ALS among different populations. In Caucasians the 
incidence of ALS is about 2 cases per 100′000 per year and the 
prevalence is approximately 6–8 per 100′000 (Logroscino et al., 
2010). Incidence rates increase with age, with a peak between 70 
and 80 years, and men are more frequently affected than women. 
The first characterization of ALS was performed in 1869 by the 
French medical doctor Jean-Martin Charcot, who deduced the 
relationship between the clinical signs and the autopsy findings 
(Charcot, 1869; Charcot et al., 1874). Ten years later, in 1880, the 
Canadian medical doctor William Osler reported the first familiar 
form of ALS with autosomal dominant inheritance, described in a 
family from Vermont, which, more recently, has been shown to 
have a mutation in SOD1 gene (Osler, 1880; Roulea et al., 2007). In 
1993 mutations in the gene coding for the superoxide dismutase 1 
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(SOD1) were associated, for the first time, with the onset of one of 
the familiar forms of ALS (Rosen et al., 1993). 
The relevant pathological feature of ALS is the progressive injury 
and cell death of lower motor neuron groups in the spinal cord and 
brain stem, and of upper motor neurons in the motor cortex. The 
disease is clinically characterized by progressive muscle weakness, 
atrophy and spasticity resulting in the end in complete paralysis of 
voluntary muscles, leading to death by respiratory insufficiency. 
Almost all the muscle functions became impaired with the 
exception of those controlling the bladder, the sphincters and the 
eye movement, which are affected only in the very late stage of the 
disease (Kandel et al., 1991).  
ALS is conventionally classified in two categories depending on the 
history of the patients. If patients have affected relatives, they are 
classified as familial ALS (FALS) cases, otherwise they are 
considered as sporadic ALS (SALS) ones. FALS accounts for 5-
10% of all cases and is predominantly autosomal dominant 
inherited; lots of genes have been identified that are mutated and are 
responsible for the onset of FALS cases (Verma et al., 2013). On 
the other side the causes of SALS are still not known. Clinically, 
FALS and SALS are very similar, and this is really encouraging, 
because the study of the molecular and cellular basis of FALS 
might provide understanding into the pathogenesis of SALS. 
Different environmental risk factors has been suggested as causative 
of ALS onset, and the most significant associations are with 
advancing age and exposure to tobacco smoke, but currently there 
are also other evidences supporting the contribution of other 
environmental risk factors (Table 1) (Nelson et al., 2000; 
Wijesekera et al., 2009) 
 
1.1.1 - Molecular and cellular pathways in ALS 
The pathogenesis of ALS is not clear, and the exact mechanism that 
leads to cell death is currently not known. A lot of evidences 
described in patients suggest that the neurodegenerative processes 
occurring in ALS could be the results of a complex interplay 
between multiple mechanisms. These include genetic factors, 
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Table 1. Exogenous risk factors implicated in sporadic ALS: 
- Age at menopause (females) 
- Dietary factors 
- Electrical injury 
- Family history of non-ALS neurodegenerative disease 
(Parkinson's or Alzheimer's disease) 
- Geographical residence (rural, suburban or urban) 
- Gulf war service (Male veterans) 
- Maternal age, Number of births (in females) & Birth order, 
Loss of child 
- Occupation 
- Physical activity 
- Playing football professionally 
- Previous poliomyelitis infection 
- Race/ethnicity 
- Smoking 
- Toxin exposure (agricultural chemicals, lead) 
- Trauma (e.g. Head injury) 
- Years of education 
(from Wijesekera et al., 2009) 
 
oxidative stress, excitotoxicity, protein aggregation, damage to 
critical cellular processes, including axonal transport, and to 
organelles, such as mitochondria (Shaw, 2005; Figure 1). Due to the 
specificity of ALS clinical and cellular features, and due to the large 
spectrum of genetic/risk factors and pathway altered in ALS, it has 
been proposed that all these different elements lead to ALS 
pathology through a downstream common pathway yet 
undiscovered. Nevertheless the description and the characterization 
of all the altered regulatory networks in ALS might help its 
identification. 
 
Oxidative stress and mitochondrial dysfunction. Oxidative stress 
arises when the levels of Reactive Oxygen Species (ROS) exceed 
the amounts required for normal redox signaling. Notably high 
levels of ROS have been detected in the cerebrospinal fluid and in  
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the spinal cord of SALS patients (Tohgi et al., 1999). ROS cause 
permanent oxidative damage to major cellular components such as 
proteins, DNA, lipids, and cell membranes (Bogdanov et al., 2000; 
Girotti 1998; Shaw et al., 1995). The oxidative stress has been 
particularly studied in ALS, also because in about 20% of FALS 
cases the causative mutation resides in the SOD1 gene, which 
encodes for a cellular antioxidant defense protein. 
Even though increased levels of markers of oxidative stress have 
been consistently observed in ALS, the origin of oxidative stress 
and the exact role of ROS in disease processes are still not clear 
(Barber et al., 2010). It has been proposed that oxidative stress in 
Figure 1. Molecular and cellular pathways in Amyotrophic Lateral 
Sclerosis. Schematic representation of ALS-associated pathway. ALS is a 
complex disease involving activation of several cellular pathways in motor 
neurons, and deregulated interaction with neighboring glial cells (Ferraiuolo 
et al., 2011). 
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ALS may be caused by a misbalanced metabolism of iron (Carrì et 
al., 2003; Jeong et al., 2009). Neurons are non-dividing cells, and 
the effects of oxidative stress may be cumulative, and injury by free 
radical species is one of the causes of the age related deterioration 
in neuronal function that occurs in neurodegenerative diseases.  
Age related deterioration of mitochondrial function is considered a 
potentially important factor that contributes to late onset of 
neurodegenerative diseases. There are a lot of evidences, from ALS 
patients and animal models, indicating mitochondrial function 
failure as a central issue in ALS pathogenesis. Mitochondria are 
both the major site of ROS formation and, at the same time, are 
particularly susceptible to oxidative stress. Therefore, when 
mitochondria are damaged, they release ROS, which, in turn, are 
able to induce additional mitochondrial damage (Lin et al., 2006).  
When mitochondria are damaged in ALS, they have altered 
morphology and functions, and membrane permeability, leading to 
elevated calcium levels and decreased activity of respiratory chain 
complexes I and IV, implicating defective energy metabolism. The 
increased concentration of calcium in the cell induces the activity of 
several enzymes that generate toxic ROS, amplifying the ROS 
mediated toxicity (Adam-Vizi et al., 2010). 
 
Protein aggregation and impairment of axonal transport. 
Aggregates of disease-linked mutant proteins are hallmarks of 
neurodegenerative diseases and, in particular, of ALS. These 
aggregates are frequently found in spinal motoneurons of all types 
of ALS patients and disturb normal protein homeostasis inducing 
cellular stress (Bendotti et al., 2013). They interfere with different 
cellular functions, including mitochondrial function and 
intracellular transport, and the derived stress leads to axonal 
retraction and cell death. These aggregates found in ALS patients 
contain ubiquitinated inclusions of many different proteins, some of 
which may have a known intrinsic tendency to aggregate (SOD1, 
TDP43, FUS, and OPTN). Interestingly, FUS and TDP43 ALS-
associated mutations enhance the rate of aggregation of these 
proteins (Johnson et al., 2009; Sun et al., 2011). 
Protein aggregates result toxic for motoneurons, because they may 
trap proteins with important functions for the cell, and, on the other 
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side, these aggregates may impair the axonal transport causing 
mechanical impedance. In SOD1 mutant mice, defects in axonal 
transport are well documented, and this defect clearly precedes ALS 
symptoms (Bilsland et al., 2010).  
 
Excitotoxicity. Excitotoxicity consists on neuronal injury caused by 
excessive glutamate induced stimulation of the postsynaptic 
glutamate receptors. This excessive stimulation leads to a massive 
calcium influx in the cell that cause increased nitric oxide formation 
and thereby neuronal death (Shaw, 2005). This was one of the first 
theories proposed for motoneuron degeneration in ALS, based on 
the evidence that increased levels of glutamate were observed in the 
cerebrospinal fluid of patients (Rothstein et al., 1992). Later, an 
association between motoneuron degeneration in ALS and the 
impairment of the astroglial glutamate transporter EAAT2 has been 
demonstrated, but seems to be a secondary effect rather than a 
primary one in ALS onset (Bendotti et al., 2001). 
 
Contribution of non-neuronal cells and inflammatory 
dysfunction. Although motoneurons are the main impaired cells in 
ALS pathogenesis, there is extensive evidence that non-neuronal 
cells and inflammatory dysfunction contribute to this disease. Glial 
cells play an important role in the pathology onset.  
Recent evidence revealed that, in particular, oligodendrocytes 
activity contributes to ALS onset. In murine models of ALS, 
oligodendrocytes degenerate but are constantly replaced; however, 
these replaced cells appear to be insufficient in terms of metabolic 
and trophic support, contributing to the motor neuron loss in ALS 
(Lee et al., 2012). Studies of mutant SOD1 mice have shown that 
motoneuron death in ALS is non-cell autonomous, since other cells 
contribute to disease onset, as astrocytes and microglia (Ilieva et al., 
2009). In ALS patients, these cells are progressively activated as the 
disease progresses, initiating the process known as 
neuroinflammation. This process has a dual role: on one side, it has 
a protective role through the modulation of the helpful 
inflammatory response thus slowing disease progression (Beers et 
al., 2012). On the other side, at later stage, this persistent activation 
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becomes toxic. In this inflammatory condition, motoneurons 
continue to release factors that activate microglia, that in turn starts 
being proinflammatory and neurotoxic, enhancing motoneuron 
damage (Appel et al., 2011). Furthermore, astrocytes expressing 
mutated SOD1 release factors that are selectively toxic to 
motoneurons and induce wild type motoneurons degeneration in 
vivo (Papadeas et al., 2011). 
 
1.1.2 - Genetics of ALS 
A lot of genes have been associated with ALS onset (Table 2). The 
mutations of these genes cause the onset of the pathology, and the 
inheritance is almost always autosomal dominant. The first link 
between an ALS-associated gene and chromosome 21 was 
discovered in 1991 (Siddique et al., 1991). Only two years later the 
gene associated with FALS was identified as SOD1, coding for a 
copper-zinc superoxide dismutase (Rosen et al., 1993). Mutations in 
this gene have been found in 12–23% of FALS (Sabatelli et al., 
2013). Even though a decrease of dismutase activity in ALS 
patients was immediately observed (Deng et al., 1993), it has been 
well demonstrated that this lack of dismutase activity is not the 
primary cause of ALS, since not all the mutations affect normal 
enzymatic activity. Therefore it has been shown that mutations in 
SOD1 confer a toxic additional function to the protein, probably 
linked to the intracellular localization of the mutant enzyme (Carrì 
et al., 2012). Mutant SOD1 causes neurodegeneration by affecting 
mitochondria homeostasis, neurofilaments and axonal transport, 
functions of endoplasmic reticulum and proteasome (Pasinelli et al., 
2006). Since SOD1 identification, many other genes have been 
linked to ALS disease and they are the cause of about 70-80% of 
FALS cases (Table 2). In 2006 TDP43 (TAR DNA-binding protein 
43) has been identified as the main component of the ubiquitinated 
aggregates found in some FALS patients (Arai et al., 2006; 
Neumann et al., 2006). In these patients a reduction of the amount 
of TDP43 protein in the nucleus was observed, suggesting that in 
this patients the pathogenesis of ALS could be due to a loss of 
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Table 2: Genes mutated in ALS 
Mutated gene Gene locus Inheritance 
Estimated 
% of FALS 
SOD1  21q22.1 Dominant 20% 
TDP43 1p36.2 Dominant 1–5% 
FUS/TLS 16p11.2 Dominant 1–5% 
TAF15 17q11.1–q11.2 Unknown Unknown 
EWSR1 Unknown Unknown Unknown 
ANG 14q11.2 Dominant <1% 
SETX 9q34 Dominant Unknown 
C9ORF72 9p21.3–p13.3 Dominant 40–50% 
ATXN2 12q24 Dominant <1% 
UBQLN2 Xp11 Dominant <1% 
OPTN 10p15–p14 Dominant <1% 
SQSTM1 5q35 Dominant Unknown 
VCP 9p13 Dominant <1% 
CHMP2B 3p11 Dominant Unknown 
FIG4 6q21 Dominant Unknown 
DAO 12q24 Dominant <1% 
VAPB 20q13.3 Dominant <1% 
Peripherin  12q13.12 Sporadic Unknown 
DCTN1 2p13 Dominant Unknown 
NFH 22q12.2 Dominant? Unknown 
PFN1 17p13.2 Dominant Unknown 
Spatacsin  15q21.1 Recessive Unknown 
Alsin  2q33.2 Recessive <1% 
Awaits identification  18q21 Dominant Unknown 
Awaits identification  20ptel–p13 Dominant Unknown 
Awaits identification  15q15.1–q21.1 Recessive Unknown 
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function of TDP43 in this cellular compartment (Neumann et al., 
2006; Van Deerlin et al., 2008). TDP-43 is a multifunctional RNA 
binding protein, manly localized in the nucleus, involved in 
transcription, RNA splicing and transport. As a consequence of 
mutations, TDP43 delocalizes in the cytoplasm, and forms stress 
granule-based aggregates, causing ALS onset (Johnson et al., 2009). 
Another gene particularly interesting for ALS pathogenesis, is 
FUS/TLS (or FUS). In 2003 ALS was correlated to a locus in 
chromosome 16 (16q12.1-16q12.2) (Abalkhail et al., 2003), and in 
2009 were identified a lot of mutations in FUS gene as responsible 
of ALS onset (Kwiatkowski et al., 2009; Vance et al., 2009). FUS 
is mutated in about 4% of patients affected by FALS and about 1% 
of patients affected by SALS (Thomas et al., 2013). Notably FUS is 
another RNA binding protein, and, as TDP-43, is involved in 
different aspects of RNA metabolism, from transcription, to splicing 
and RNA transport. The identification of ALS-causing mutations in 
TDP43 and FUS leads to the idea that aberrant RNA metabolism 
contributes to ALS pathogenesis and the findings that a surprising 
number of proteins linked to ALS are directly or indirectly involved 
in RNA processing supported this hypothesis.  
 
1.1.3 - Diagnosis and therapies 
Despite advances in investigative medicine, diagnosis of ALS is 
based on the presence of very specific clinical features, and is based 
on examinations necessary also to rule out other diseases with 
similar symptoms (e.g. Cervical radiculomyelopathy and multifocal 
motor neuropathy). The diagnosis of ALS is primarily based on the 
symptoms and signs observed in the patient, through neurologic 
examination, in order to investigate whether symptoms such as 
muscle weakness, atrophy of muscles, hyperreflexia and spasticity 
have a progression compatible with a neurodegenerative disorder. 
Appropriate tests necessary to correlate the symptoms specifically 
to ALS must be conducted, like electromyography (EMG), a test 
that measures nerve conduction velocity (NCV) and brain and 
spinal magnetic resonance imaging (MRI). The diagnosis, when 
performed by an experienced clinician, is accurate 95% of the times 
(Rowland et al., 2010). 
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There is no cure for ALS yet, so the clinical care is finalized in 
maintaining the quality of life and prolonging life as much as 
possible. Current therapies are directed to symptomatic relief or 
replacement of neurotransmitters. However, most of these therapies 
are not able to reduce the neurodegenerative progression (Katsuno 
et al., 2012). This is due mainly to the lack of knowledge of the 
exact causative pathway of neurodegeneration, the lack of animal 
models that are able to exactly recapitulate the human pathogenesis 
and the lack of knowledge about pre-symptomatic phase. The only 
drug available for ALS patients is riluzole (6-(trifluoromethoxy) 
benzothiazol-2-amine), that is able only to extend patients survival 
of only 2-3 months (Miller et al., 2012). Beyond riluzole, a lot of 
different drugs have been tested, but no benefits for patients has 
been demonstrated (Zinman et al., 2011). 
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1.2 - FUS/TLS 
The gene FUS/TLS (fused in sarcoma/translocated in liposarcoma, 
or FUS) encodes for a 526 aminoacid protein, widely expressed in 
most of the human tissues, and mainly localized in the nucleus, 
even though cytoplasmic localization has been detected in many cell 
types (Andersson et al., 2008). Moreover, FUS carries out some of 
its functions by shuttling between the nucleus and the cytoplasm 
(Zinszner et al., 1997). FUS belongs to FET protein family, that 
includes Ewing's sarcoma protein (EWS) and TATA-binding 
protein associated factor 15 (TAFII68/TAF15). All proteins 
belonging to this family have a similar structure characterized by a 
N-terminal QGSY-rich domain, a highly conserved RNA 
recognition motif, multiple repetitions of RGG-rich domain 
implicated in RNA binding and a C-terminal zinc finger motif (Iko 
et al., 2004). In particular FUS is characterized by a Nuclear 
Localization Signal (NLS) at the extreme C-terminus, and by a N-
terminal degenerated and repeated SYGQQS sequence which, when 
fused to transcriptional factor, functions as a strong transcriptional 
activator as it happens in liposarcomas and myeloid leukaemia 
(Prasad et al., 1994; Figure 2A). 
FUS carries out many functions involved in RNA metabolism 
(Figure 2B). Different in vitro analysis demonstrated that FUS is 
able to bind both RNA and DNA molecules (Lagier-Tourenne et al., 
2010) and in particular is able to bind preferentially RNA molecules 
enriched in the GGUG sequence (Iko et al., 2004). 
FUS is involved in RNA transcriptional regulation. FUS has been 
found associated with the transcriptional machinery by direct 
interaction with RNA polymerase II and the transcription factor II D 
(TFIID), thus influencing transcription initiation and promoter 
selection (Bertolotti et al., 1998; Yang et al., 2000). FUS is also 
able to interact with specific transcription factors such as NF-Kb e 
Spi-1 (Uranishi et al., 2001; Hallier et al., 1998) thus influencing 
the transcription of the target genes. Recently it has been 
demonstrated that FUS also represses transcription of RNA 
Polymerase III (Tan et al., 2010). 
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Figure 2. (A) Schematic overview of protein domains of FUS and identified gene 
mutations associated with ALS. NES=nuclear export signal. NLS=nuclear 
localisation signal. QGSY=Gln-Gly-Ser-Tyr-rich region. RGG=Arg-Gly-Gly-rich 
motif. RRM=RNA recognition motif (adapted from Mackenzie et al., 2010). (B) 
Proposed physiological roles of FUS/TLS and TDP-43. (1) FUS associates with 
TBP suggesting its role in transcription. (2) FUS was identified as a part of the 
spliceosome. (3) Both proteins were found in a complex with Drosha, suggesting 
their role in miRNA processing. (4) Both TDP-43 and FUS/TLS shuttle between 
the nucleus and the cytoplasm and (5) are incorporated in stress granules. (6) 
Both proteins are involved in the transport of mRNAs to dendritic spines (adapted 
from Lagier-Tourenne et al., 2010). 
Mutations in the 3’UTR of FUS 
A 
1 
2 
3 
4 
5 
6 
B 
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FUS has an important role also in splicing. It has been demonstrated 
that it is able to influence the splicing of reporter genes, interacting 
with several splicing factor (e.g. Yb1, SR proteins, hnRNP A1 and 
C1/C2) (Lagier-Tourenne et al., 2010). Recent experiments of 
“individual-nucleotide resolution Cross-Linking and 
ImmunoPrecipitation” (iCLIP) carried out in mouse brain, revealed 
that FUS associates with the precursor transcripts of mRNA by 
binding preferentially GGUG enriched sequences and regulating the 
splicing process (Rogelj et al., 2012). Finally, it has been 
demonstrated that FUS is able to regulate the splicing of RNA 
binding protein coding genes, including snRNP70, which contains 
intronic sequences highly conserved that are bound by FUS 
(Nakaya et al., 2013).  
In addition FUS is involved in the regulation of nucleo-cytoplasmic 
shuttling of RNA molecules (Zinszner et al., 1996). FUS has been 
found in RNA transport granules, and is able to bind the Nd1-L 
transcripts and transport them in spines of mouse ippocampal 
neurons, where local translation takes place (Fuji et al., 2005). Nd1-
L encodes for an actin-stabilizing protein, and FUS-null mice 
neurons display abnormal spine morphology, suggesting that FUS 
may be involved in spine morphology and in actin reorganization in 
spines (Fuji et al., 2005).  
 
1.2.1 - FUS mutations and ALS: the importance of being 
regulated 
Mutations in FUS gene associated with ALS onset were described 
for the first time in 2009 (Figure 2A; Kwiatkowski et al., 2009; 
Vance et al., 2009). Mutations in FUS account for about 4% of 
FALS and less than 1% of SALS (Rademakers et al., 2010). 
Although the majority of patients carrying FUS mutations exhibits a 
classical ALS phenotype without cognitive impairment, FUS-ALS 
patients disclose some distinctive characteristics and, depending on 
the mutation, they show diverse clinical course of the disease. The 
age of onset is generally earlier than in other SALS and FALS 
patients, and some patients show juvenile onset and very aggressive 
course with survival significantly shorter than in other FALS 
(Sabatelli et al., 2013). 
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The majority of ALS-linked mutations are clustered in the extreme 
C-terminal region of the FUS protein, and almost all of them are 
missense changes (Figure 2A). Analysis of the brains and spinal 
cords of ALS patients with FUS mutations revealed that FUS is 
mislocalized and accumulated in the cytoplasm. Most of ALS-
linked mutations in FUS disrupts the nuclear import and cause the 
mislocalization of the protein in the cytoplasm, where it associates 
with stress granules that may form inclusions (Dormann et al., 
2010). When FUS is mislocalized, and the nucleus lacks the proper 
amount of this protein, FUS level may not be enough to carry out all 
its functions. On the other side, the accumulation of FUS in the 
cytoplasm could be toxic for the cell. The mutated forms of FUS 
could acquire, indeed, a new, toxic function, both in the nucleus and 
in the cytoplasm, that could alter cellular homeostasis. FUS knock-
out mice on an inbred background display perinatal death and 
exhibit abnormal lymphocytes and chromosomal instability (Hicks 
et al., 2000), whereas knock-out mice on an outbred background 
develop male sterility and exhibit increased sensitivity to ionizing 
irradiation (Kuroda et al., 2000). More recently it has been observed 
that FUS knock-out hippocampal neurons displayed abnormal spine 
morphology and a reduced number of spines (Fujii et al., 2005). 
Furthermore it has been recently demonstrated that FUS has a 
crucial role in the DNA damage response and DNA repair. FUS 
directly interacts with histone deacetylase 1 (HDAC1), and the 
recruitment of FUS to double-stranded break sites is important for 
proper DNA damage response signaling (Wang et al., 2013). On the 
other side transgenic mice overexpressing wild-type human FUS 
develop an aggressive phenotype with an early onset of several 
pathological features observed in human ALS patients (Mitchell et 
al., 2013). 
Recently, four different mutations in the 3’ untranslated region 
(3’UTR) of FUS were identified in ALS patients. In fibroblasts 
coming from these patients, it has been observed a strong increase 
of the FUS protein and, in particular, a strong accumulation in the 
cytoplasm (Figure 2A; Sabatelli et al., 2013). The 3’UTR is a 
region of mRNA where different RNA binding proteins or 
microRNAs (miRNAs) may exert their regulatory role. The 
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observation that mutations affecting only the regulatory region of 
the gene, but not the coding sequence, are causative of ALS, 
underlines the importance of FUS to be finely regulated.  
Therefore, when some of the regulatory mechanisms fail, FUS 
levels may result altered and damages for the cell homeostasis occur 
with the establishment of an ALS phenotype.  
 
  
Stefano Dini Modigliani 
 
 
Pag 24  
1.3 - Splicing 
The expression of protein-coding genes in eukaryotes starts in the 
nucleus where RNA polymerase II (RNAPII) transcribes genomic 
coding DNA sequence into a precursor messenger RNA (pre-
mRNA). The pre-mRNA must undergo a number of processing 
steps, highly regulated, to yield a mature and functional messenger 
RNA (mRNA), which is then ready to be exported and used by the 
translational machinery in the cytoplasm (Maniatis et al., 2002). In 
higher eukaryotes, most protein-coding genes contain long 
sequences (named introns) that are transcribed in the pre-mRNA 
and must be removed in a process called splicing, leaving the 
protein coding sequences (exons) appropriately aligned and jointed 
together into the mRNA. 
Splicing consists of two trans-esterification reactions that are driven 
by the spliceosome, a large ribonucleoprotein complex containing 
five small nuclear RNAs (snRNAs; U1, U2, U4, U5, and U6) and 
approximately 200 additional proteins (Montes et al., 2012) (Figure 
3A). Spliceosome assembly occurs in an ordered step-wise manner 
and leads to the identification of the cis-sequence elements that 
define the exon-intron boundaries (the 5′ and 3′ splice sites) and the 
associated 3′ sequences for intron excision (the polypyrimidine 
tract, and the branch point sequence). The two trans-esterification 
reactions are carried out with the involvement of five small nuclear 
ribonucleoprotein (snRNPs), and a lot of different proteins, 
catalyzing the intron excision and exon–exon ligation reactions. 
Exons can be excluded or included in the final mRNA molecule, 
depending on regulatory cis elements and the protein factors that 
can be involved, leading to the formation of different mature 
mRNAs. 
Alternative splicing, the event by which the same pre-mRNA can be 
spliced in different ways leading to the formation of different 
mature mRNAs, contributes significantly to the diversity of the cell 
and to the tissue specific protein expression profiles (Maniatis et al., 
2002) (Figure 3B). Through alternative splicing, one single gene 
may give rise to many different protein isoforms, often with distinct  
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Isoform 1 
Isoform 2 
A 
B 
pre-mRNA 
Figure 3. Pre-mRNA splicing. (A) Upper panel: schematic representation of 
a metazoan pre-mRNA, with two exons at the 5’ and 3’ ends, separated by an 
intron. Lower panel: schematic representation of the two trans-esterification 
reactions driven by the spliceosome that lead to the formation of the mature 
mRNA. (B) Schematic representation of an alternative splicing event. From 
the same pre-mRNA, through the inclusion of different exons in the mature 
mRNA, can be produced different isoforms, with different function. 
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functions. From deep-sequencing based expression analyses, 
emerged that more than 90% of multi-exonic human genes undergo 
alternative splicing (Wang et al., 2008). In Homo Sapiens, the brain 
shows the highest level of alternative spliced genes, with more than 
40% of genes being alternatively spliced (Yeo et al., 2004). 
Interestingly, the suboptimal arrangement and poor conservation of 
the cis-elements are an essential property of eukaryotes, in which 
the sequences are sensitive to the combinatorial regulation exerted 
by different splicing factors, that in different conditions can 
influence the alternative splicing events (Izquierdo et al., 2006). 
There are other cis-elements that are able to regulate alternative 
splicing, known as exonic and intronic splicing silencers or 
enhancers (ISS, ISE, ESS, and ESE). These elements are recognized 
by specific RNA-binding proteins that include heterogeneous 
nuclear ribonucleoproteins (hnRNPs) and serine/arginine-rich (SR) 
proteins (Wu et al., 1993). These are positive and negative 
regulators of splicing that, in combination with a lot of additional 
auxiliary regulators, produce a huge number of potentially different 
combinations of elements that vary among different tissues and 
distinct homeostatic environments (Lin et al., 2007).  
It is widely accepted that transcription and splicing are physically 
and functionally related and they can be reciprocally influenced. 
When RNAPII starts transcribing, the carboxy-terminal domain 
(CTD) and transcription elongation factors play central roles in 
recruiting splicing factors on pre-mRNA (Maniatis et al., 2002). 
This coupling implies that splicing occurs co-transcriptionally, with 
only few exceptions in which this process can also be post-
transcriptional. The transcriptional rate can influence pre-mRNA 
splicing. Subcanonical splicing sequences are more efficiently 
recognized by splicing machinery when RNAPII is slow, while 
when RNAPII is transcribing fast, canonical splicing sequences are 
the most easily recognised by the splicing machinery (Kornblihtt et 
al., 2004).  
 
1.3.1 - Splicing and disease 
Most of the hereditary diseases are caused by point mutations, and 
more than 80% of them are reported as missense or nonsense 
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mutations. Notably, about 50% of the mutations results in aberrant 
splicing (Lopez-Bigas et al., 2005). Alternative spicing, or aberrant 
splicing lead to deletions or substitutions of protein domains, to 
frameshift, or to premature stop codon formation. When mutations 
lead to the formation of a truncated isoform of a protein, this could 
be pathological for two reasons: on one side, there is no more 
production of the full-length protein; on the other side, this smaller 
isoform could have a new dominant-negative function, pathogenic 
for the cell. Alternative spicing, or aberrant splicing, can also lead 
to exon skipping, causing a frameshift and inducing the formation 
of a premature stop codon. Transcripts like this are then recognized 
by the cell as non-functional, so they are degraded by nonsense-
mediated mRNA decay (NMD), reducing the amount of the full-
length transcript, and so the amount of the protein in the cell.  
Splicing can be altered by both mutations in cis elements, and 
alterations in trans factors involved in this processes. One example 
regards CTRF gene, whose mutations are associated with cystic 
fibrosis. About 25% of synonymous variants resulted in altered 
splicing inducing exon 12 skipping (Pagani et al., 2005). So even 
without changing the coding properties of a gene, point mutations 
can alter the correct splicing leading to the alteration of the 
functionality of the final protein product and then to pathology 
onset.  
 
1.3.2 – FUS, splicing and ALS 
Recent experiments of “high-throughput sequencing of 
immunoprecipitated and cross-linked RNA” (HITS–CLIP) revealed 
that FUS is one of the proteins involved in splicing regulation. FUS 
is able to regulate the splicing process of a lot of coding genes, and 
FUS knockdown altered the expression of more than 1000 exons in 
the mouse neuronal transcriptome (Nakaya et al., 2013). 
Interestingly, among the gene regulated by FUS, there are a lot of 
genes coding for RNA-binding proteins (RBP) and carrying highly 
conserved introns (Nakaya et al., 2013). The observation that FUS 
participates in an extensive network of cross-regulation of other 
RBPs by targeting their conserved introns, suggest that 
perturbations of FUS in ALS may lead to changes in the 
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transcriptome, as a result of direct effects of FUS on bound 
transcripts and of secondary effects through other RBPs regulated 
by FUS. 
Notably, FUS is also able to bind its own pre-mRNA, in particular 
FUS is able to bind the 3’UTR and the region between exon 6 and 
exon 8 (Lagier-Tourenne et al., 2012). This region is particularly 
conserved and this is an unusual feature for intronic sequences, 
suggesting that this region may be involved in some regulatory 
events. FUS intracellular levels must be extremely regulated, and 
these evidence comes from the observations that increased amounts 
of FUS can lead to ALS pathogenesis (Sabatelli et al., 2013). 
Moreover the overexpression of wild type FUS in mice causes the 
development of an aggressive phenotype with pathological features 
observed in human ALS patients (Mitchell et al., 2013). Notably, 
the exogenous overexpression of FUS in these mice induced a 
decrease of the endogenous FUS protein. These observations 
suggest that FUS could be involved in some autoregulatory 
mechanisms acting on its own pre-mRNA. So, it would be really 
interesting to elucidate in which way FUS can regulate itself, in 
order to understand which aspects of this regulatory mechanisms are 
altered in ALS patients. 
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1.4 - MicroRNAs 
MicroRNAs (miRNAs) are a large class of small (about 18-23 
nucleotides) non-coding RNAs involved in a variety of biological 
processes by regulating gene expression at the post-transcriptional 
level. The first miRNA identified is lin-4, discovered 20 years ago 
during the study of C. elegans larval development (Lee et al., 
1993). Lin-4 gene was demonstrated to give rise to a small RNA of 
22 nucleotides in length able to interact with the 3′-UTR of the lin-
14 mRNA, leading the repression of lin-14 expression (Wightman 
et al., 1993). It took other 7 years to discover the second member of 
this class of RNAs, let-7 (Reinhart et al., 2000). Since then, 
research attention on miRNAs studies has increased exponentially 
in the years, leading the discovery that miRNAs are conserved 
among organisms (Pasquinelli et al., 2000) and are present in 
almost all eukaryotes (Bartel et al., 2004). In the human genome 
1872 miRNA genes have been identified (as categorized by the 
release 20 of miRBase; Kozomara et al., 2013). MiRNAs are 
expressed in all human tissues, and lots of them are tissue specific 
and participate in the regulation of pivotal biological processes, like 
development, differentiation and stimuli response. It has been 
estimated that one miRNA is able to recognise and target up to 
hundreds of mRNAs, and, on the other side, a mRNA could be 
potentially regulated by different miRNAs (Brennecke et al., 2005). 
Bioinformatic analysis predicted that about 60% of protein-coding 
genes can be post-transcriptionally regulated by miRNAs (Friedman 
et al., 2009). These assessments underline the importance of the 
regulatory network in which miRNAs are involved and the 
importance of increasing our knowledge on miRNA field to better 
understand the regulatory mechanisms that are important for the 
cellular metabolism.  
 
1.4.1 - miRNA biogenesis 
miRNA biogenesis starts in the nucleus where RNAPII, or, in 
particular situations, RNAPIII, transcribe genes coding for miRNAs 
leading the formation of long precursor transcripts named primary 
miRNAs (pri-miRNAs) (Figure 4). Pri-miRNAs can contain one or  
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Figure 4. microRNA biogenesis. After transcription by RNA Polimerase II 
or III, the pri-miRNA is first cropped by the microprocessor into a ~70 nt 
hairpin pre-miRNA. The core components of the microprocessor are Drosha 
and DGCR8. The pre-miRNA is then exported by RanGTP and Exportin-5 to 
the cytoplasm. In the cytoplasm, another RNAse III endonuclease, Dicer, is 
responsible for dicing pre-miRNAs into short RNA duplexes termed miRNA 
duplexes. After Dicer processing, the miRNA duplex is unwound and the 
mature miRNA binds to an Argonaute (Ago) protein, while the other molecule 
is degraded. The miRNA/Ago ribonucleoprotein that is formed represents the 
core component of the effector complexes that mediate miRNA function and 
is known as miRNP (adapted from Liu et al., 2007). 
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several miRNAs embedded in characteristic stem loop hairpin 
structures. Many miRNA-coding sequences overlap with annotated 
genes for coding or non-coding RNAs, which are referred to as 
“host” genes. However, pri-miRNA sequences are not extensively 
characterized and when is localized within or near a known gene, it 
is often assumed that transcription of the host gene produces a 
transcript that ultimately gives rise to the miRNA. However, often 
occurs also that this miRNA has its own promoter, suggesting that it 
is independently transcribed and regulated regardless of the “host” 
gene.  
In the canonical pathway, a pri-miRNA is cleaved by the 
Microprocessor complex, composed mainly of Drosha and its RNA-
binding protein partner, DGCR8. The cleavage occurs often while 
the pri-miRNA is still associated with the chromatin (Morlando et 
al., 2008; Ballarino et al., 2009). Drosha is a 160Kda protein 
belonging to the RNAse III family, with two RNAse III domains 
and a domain able to bind double-stranded RNAs molecules 
(dsRBD). The cleavage catalysed by Drosha leads to the formation 
of a 2-nt 3’ overhang that is necessary for the recognition by the 
other factor involved in the following biogenesis process (Lee et al., 
2003). DGCR8 is an essential cofactor that is able to recognise the 
pri-miRNAs, in particular it binds the junction between the ssRNA 
and the dsRNA of the stem-loop structure, recruiting Drosha to 
cleave the stem loop 11 nucleotides away from the ssRNA-dsRNA 
junction (Han et al., 2006). The Microprocessor activity leads to the 
formation of a precursor molecule of about 70 nucleotides, named 
pre-miRNA, that maintains the typical stem-loop structure 
(Mourelatos et al., 2002) and that is exported to the cytoplasm by 
Exportin-5 (Yi et al., 2003). 
For miRNA genes localized in the intron of a host gene, the pri-
miRNAs sequences are processed co-transcriptionally, when the 
host gene transcript is still not spliced (Kim et al., 2007). This is 
possible because the Microprocessor acts co-transcriptionally 
without altering the splicing of the host-gene (Morlando et al., 
2008). Therefore, from the same transcript both the mRNA and the 
miRNA molecules can be generated. 
In the cytoplasm the pre-miRNA is processed by Dicer, another 
endonuclease that belongs to the RNAse III family (Bernstein et al., 
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2001). Dicer recognizes the 2-nt 3’ overhang produced by Drosha 
cleavage, and with its two endonucleolytic domains Dicer cleaves 
the hairpin structure at the base of the apical loop, leading to the 
formation of another 2-nt 3’ overhang and producing a miRNA 
duplex intermediate of about 22 base pairs (Zhang et al., 2004). 
These RNA duplexes are then separated and only one of the strands 
is selected as the mature miRNA, while the other is rapidly 
degraded. Mature miRNAs are incorporated into Argonaute 2 
(Ago2) protein-containing effector complex, known as miRNP 
(miRNA-containing ribonucleoprotein complex). Ago2 is composed 
mainly of a PAZ domain, responsible for the binding of the 3’end of 
mature miRNAs, a MID domain, responsible for the binding of the 
5’end, and PIWI domain with endonucleolytic activity (Mourelatos 
et al., 2002). MiRNPs contain also GW182, a protein rich in glycine 
and tryptophan aminoacids important for the recruitment of a large 
amount of factors involved in mRNA silencing (Chekulaeva et al., 
2011). 
 
1.4.2 - miRNA mechanisms of action 
In mammals, miRNA sequences guide miRNP to the target mRNA 
by imperfect complementary to the miRNA response element 
(MRE), leading to translational repression and/or accelerated 
mRNA decay (Liu et al., 2007). The sequences recognized in the 
mRNAs are almost always localized in the 3’UTR (Filipowicz et 
al., 2005). The only portion of the miRNA that generally binds 
perfectly to the MRE is localized between nucleotides 2 and 8 and 
is called “seed”. It plays a pivotal role in target recognition (Doench 
et al., 2004), even though the other nucleotides of the miRNA can 
also influence the binding affinity (Grimson et al., 2007). After the 
interaction between miRNP and mRNA, this complex localizes in 
specific cytoplasmic regions named Processing bodies (P-bodies) 
(Liu et al., 2005). P-bodies are dynamic structures involved in 
mRNA degradation or in accumulation of mRNA translationally 
repressed. The localization of miRNP complexes in P-bodies could 
prevent ribosomal association thus contributing to translational 
repression. In particular conditions, repressed mRNAs can be 
subsequently reactivated and translated again after P-bodies 
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disassembly, as for instance, in response to oxidative stress 
(Brengues et al., 2005). A lot of effort has been dedicated to the 
study of the mechanism of action of miRNAs, and different models 
have been proposed. Protein synthesis is a step-wise process that 
requires the involvement of a variety of factors. First of all, 
eukaryotic translation initiation factor 4E (eIF4E) binds the 7-
methyl-guanosine (cap) of the 5’end of mRNA. In addition eIF4E 
binds to the initiation factor 4G, that, in turn, recruits the 40S 
ribosomal subunit and interacts with poly(A) tail bind protein 
(PABP) at the 3’end of mRNA. All these interactions lead to the 
circularization of the mRNA by joining together the 5’ and 3’ ends 
of the molecule (Richter et al., 2005). A first model theorises that 
miRNA inhibition may occur at early step of translation in different 
ways. In Drosophila it has been observed that miRNAs are able to 
inhibit the recruitment of the ribosomal subunits through the action 
of EIF6, recruited by the miRNP complex (Thermann et al., 2007; 
Chendrimada et al., 2007). Furthermore Ago2 could compete with 
eIF4E for the binding with the cap, inhibiting the formation of the 
translation initiation complex (Mathonnet et al., 2007). Another 
theory states that miRNAs are able to inhibit mRNA translation 
either by co-translational degradation of the nascent polypeptide or 
by premature dissociation of ribosomal complexes after the 
translation initiation (Petersen et al., 2006). Lastly, another model 
supports the idea that miRNAs induce the deadenylation of the 
poli(A) tail at the 3’ of the mRNA, leading to a destabilization and 
lastly to a degradation of the mRNA (Bagga et al., 2005; Giraldez et 
al., 2006). It is reasonable to assume that different miRNAs perform 
their function in different ways depending on the target transcripts 
and the cofactors recruited.  
 
1.4.3 - Regulation of miRNAs biogenesis 
The expression of miRNAs themselves is subjected to regulation 
through a variety of mechanisms that impact every step of their 
biogenesis. MiRNAs expression levels vary depending on cell type, 
cellular differentiation stage, and on stimuli that the cell or the 
tissue receive (Landgraf et al., 2007). 
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The first step that can be regulated, is the transcription of miRNAs. 
A lot of different transcriptional factors associated to RNAPII are 
able to modulate miRNA expression. For example, Miogenin and 
MyoD are able to bind promoter regions of miR-1 and miR-133 
inducing their expression during myogenesis (Liu et al., 2007). 
MiRNAs often reside inside other genes, so in these situations the 
expression of the miRNA could be dependent on the expression of 
the host gene. Also epigenetic modifications can contribute to the 
regulation of miRNA expression. For example in T-cell 
lymphomas, miR-203 chromatin locus is highly methylated if 
compared with normal T-cells, leading the expression of the 
miRNA only in the latter situation (Bueno et al., 2008). 
Recently, a lot of mechanisms that regulate miRNAs expression at 
post-transcriptional level have been characterized. For example, the 
factor Smad4 is able to contribute to miR-21 processing. After 
specific stimuli, Smad4 translocates into the nucleus, where binds to 
the Microprocessor complex through p68 factor and enhances pri-
miR-21 processing (Hata et al., 2009). Another miRNA that is post-
transcriptionally regulated is miR-18a. The loop sequence of pri-
miR-18a is particularly conserved and is able to bind hnRNP A1 
protein. This binding causes a relaxation of the structure that leads 
to a more efficient Drosha processing (Michlewski et al., 2008). In 
this paper the authors performed a bioinformatic analysis from 
which emerged that 14% of human pri-miRNAs has a conserved 
loop sequence. The authors suggested that this conservation might 
have a functional meaning: for an efficient processing of this pri-
miRNAs the loop structure may serve as platform for the binding of 
cofactors that help Drosha processing. 
On the other side, one miRNA whose processing is inhibited post-
transcriptionally is let-7. It has been demonstrated that LIN-28 
protein is able to bind let-7 loop sequence, inhibiting the efficient 
processing by the Microprocessor (Newman et al., 2008; 
Viswanathan et al., 2008). It has been proposed that LIN-28 is also 
able to inhibit let-7 pre-miRNA processing interfering with Dicer 
activity (Rybak et al., 2008). LIN-28 is, indeed, able to recruit a 
Terminal Uridil Transferases (TUTase) that adds an Uridin tale at 
the 3’ end of the pre-miRNA. This modification blocks Dicer-
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mediate processing and leads the pre-miRNA to degradation (Heo et 
al., 2009).  
Recently emerged that also editing events are able to influence 
miRNA processing. The editing is a process in which RNA 
sequence is modified by ADAR enzymes, that are able to deaminate 
adenosines into inosines (Reenan, 2001). For example, two 
adenosines of miR-151 stem are deaminated by ADAR1. The 
deamination causes a complete inhibition of the processing 
mediated by Dicer, with an accumulation of the precursor molecules 
(Kawahara et al., 2007). 
From these data is clear that the regulation of the expression of the 
miRNAs is very complex, and that the study of the factors involved 
in these regulative mechanisms is particularly interesting.  
In 2004 Gregory laboratory has identified a lot of different cofactors 
associated with Drosha, and among them it has been found the 
protein FUS (Gregory et al., 2004). Since FUS is mutated in about 
4% of FALS and less than 1% of SALS, it is really interesting to 
study whether FUS has a role in miRNA biogenesis and whether in 
miRNA levels are altered in ALS patients. 
 
1.5 - FUS, miRNAs and neuronal differentiation 
In the neuronal system, miRNAs are extremely abundant and 
regulate pivotal processes like differentiation, synaptogenesis and 
neuronal plasticity (Kosik et al., 2006). The deregulation of these 
control mechanisms carried out by miRNAs might lead to severe 
consequences in the cellular metabolism. There are a lot of diseases 
in which altered levels of miRNA expression have been observed, 
as in Tourette, in Fragile X syndrome and in brain tumours (Barbato 
et al., 2009). A miRNA particularly interesting for its role in 
neuronal differentiation is miR-9. miR-9 is able to inhibit 
translation of REST, a transcriptional repressor that is highly 
expressed in pluripotent stem cells while it decreases in neural 
precursors and in neuronal cells. Therefore, miR-9, inhibiting the 
expression of REST, contributes to a correct differentiation of 
neuronal cells. In several neurodegenerative diseases, a deregulation 
of the expression of REST has been described, underlying the 
importance of REST and the importance of its regulation for a 
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correct neuronal differentiation program (Packer et al., 2008). Due 
to the ability of FUS to bind DNA and RNA molecules (Lagier-
Tourenne et al., 2010), and to participate in the neuronal 
differentiation and neuronal activity (Cozzolino et al., 2012), it 
turns out to be very interesting to study if this protein is involved in 
miRNA biogenesis. Its regulative effects could be both at 
transcriptional and post-transcriptional levels, and in the latter 
situation, FUS could act both in miRNA processing and transport.  
Altered FUS localization has been observed not only in ALS, but 
also in other neurodegenerative diseases. In particular, it has been 
observed that FUS binds to Neuronal intranuclear inclusions (NIIs) 
in brain of patients with spinocerebellar ataxia type 1, 2, 3, and 
dentatorubralpallidoluysian atrophy (Doi et al., 2010). Furthermore, 
FUS is the major component of nuclear polyQ aggregates of a 
cellular model of Huntington disease, and in this context the soluble 
form of FUS is reduced (Doi et al., 2008). The change of FUS to an 
insoluble form may be a common process among the diseases with 
the formation of polyQ aggregates and ALS. Thus to understand 
FUS molecular mechanisms of action could help to understand the 
pathological phenotypes observed in those diseases in which FUS 
activity is compromised. 
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2 - AIMS 
FUS is a protein implicated in a wide range of cellular processes, 
including transcription and mRNA processing. Recently, mutations 
in FUS gene were reported to be associated with familial forms of 
Amyotrophic Lateral Sclerosis (FALS) thus increasing the interest 
in this protein and suggesting a crucial function in neural cells. 
FUS shows a predominant nuclear localization even though it is 
known to shuttle between the nucleus and the cytoplasm; however, 
ALS-linked mutations lead to predominance of cytoplasmic versus 
nuclear FUS localization. Even though the exact mechanism by 
which this protein becomes pathogenic in ALS remains uncertain, 
many evidences infer that the toxicity of FUS mutants is somehow 
related to this nucleus/cytoplasmic imbalance. 
One interesting observation regarding FUS function was derived 
from data indicating the Drosha protein as a putative FUS 
interactor. Since Drosha is an essential component of the 
microprocessor complex, required for miRNA biogenesis, and its 
activity may be modulated by regulatory proteins, it has been 
suggested that FUS may regulate miRNA expression by modulating 
the activity of this processing enzyme.  
In this thesis I analyzed the FUS mode of action in the control of 
miRNA biogenesis in neuronal cells. Then I aimed to clarify the 
impact of the mutations of FUS in this biological process and in 
ALS pathogenesis. miRNAs are small non-coding RNAs that are 
involved in the post-transcriptional regulation of gene expression, 
and their deregulation is involved on the onset of many diseases. 
The study of FUS impact on miRNA biogenesis and of the role of 
ALS-associated mutations, that could result in altered miRNA 
production, could provide a possible link between deregulation of 
miRNA expression and ALS pathogenesis. 
On the other side I was interested in another aspect of FUS on ALS 
pathology: it is well documented that FUS levels are crucial for the 
cell homeostasis, and that increased amounts of FUS are associated 
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to ALS onset. More recently new ALS-associated mutations in the 
FUS gene were discovered in the 3’UTR , which are linked to 
increased protein levels (Sabatelli et al., 2013). These mutations 
lead to ALS onset, even if the FUS protein is wild type. In this 
project I analysed the mechanisms that are involved in the 
maintenance of the correct cellular levels of FUS. I showed that 
FUS is able to bind its own pre-mRNA (intron 7), therefore I 
evaluated the role of FUS in the splicing process. In addition I 
assessed a potential role of miRNAs in controlling the expression of 
FUS by binding its 3’UTR. The study of the regulatory mechanisms 
that control FUS levels is crucial to understand which are the altered 
pathways that leads to FUS accumulation and ALS onset. 
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3 - RESULTS 
3.1 - The expression of a subset of microRNAs is 
altered upon FUS knock down 
miRNAs are particularly enriched in the nervous system, where 
they carry out a crucial role in neuronal differentiation, in 
synaptogenesis and in plasticity (Kosik et al., 2006). As a 
consequence of this, miRNA deregulation can lead to severe 
consequences in the correct differentiation and functioning of neural 
cells. For this reason I used the SK-N-BE cell line derived from 
human neuroblastoma as a model system for the study of FUS and 
miRNA expression during neuronal differentiation. SK-N-BE cells 
can be induced to differentiate into neuronal like cells by treatment 
with all-trans retinoic acid (RA). 
Differentiated SK-N-BE cells were utilized to test the effect of FUS 
downregulation on miRNA expression. Cells treated with control 
(siScr) and anti-FUS siRNAs (siFUS) were analysed at 6 days after 
retinoic acid-induced differentiation. At this time point, most of the 
miRNAs playing a crucial role in neuronal differentiation reach the 
strongest up-regulation while the N-MYC protein, present only in 
proliferating cells, is downregulated (Laneve et al., 2007; Figure 5). 
6 independent experiments have been carried out and an average 
reduction of about 75% of FUS protein was obtained (Figure 6A). 
miRNA expression profiling was performed through high-
throughput quantitative real time PCR: out of 377 miRNAs, 166 
were deregulated more than 15%, with the majority (90%) being 
downregulated (Figure 6B). Among these, several miRNAs known 
to have a crucial role in neuronal function, differentiation and 
synaptogenesis (miR-9, miR-125b and miR-132; Laneve et al., 
2007 and 2010; Packer et al., 2008; Edbauer et al., 2010; Pathania 
et al., 2012) were found. Notably, the protein levels of the 
microprocessor major components, Drosha and DGCR8, were 
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Figure 5. SK-N-BE cells in vitro differentiation. SK-N-BE cells were 
induced to differentiate with retinoic acid (RA) and incubated for the 
indicated times (0, 1, 3, 6 and 10 days). Upper Panel: miR-9, miR-125b and 
miR-132 were analyzed by Northern blot using corresponding specific 
oligonucleotides. 5.8S rRNA was used as internal control. The histogram 
indicates the relative levels normalized for the 5.8S signal. Lower panel: 
Western blot analysis of N-Myc and FUS proteins at the same time points. 
GAPDH was used as internal control. 
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Figure 6. Knockdown of FUS in SK-N-BE cells. (A) SK-N-BE cells were 
treated with anti-FUS siRNA (siFUS) or control siRNA (siScr) and 
maintained in retinoic acid for 6 days. Levels of FUS, Drosha and DGCR8 
were analyzed by Western blot. GAPDH was used as a loading control. (B) 
miRNA profiling in SK-N-BE cells treated with anti-FUS siRNA (siFUS) or 
with control siRNA (siScr), cultured in RA for 6 days. Pie charts and table 
show the percentage of miRNA derelegulated more than 15%. (C) miRNA 
levels from the same cells were analyzed by qRT-PCR, and normalized for 
the snoRNA-U25 internal control. Significance was assessed by Unpaired 
Student’s t-test (*P<0.05, **P<0.01, ***P<0.001). 
  
downregulated 149 79%
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upregulated 17 9%
Total 188 100%
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unaffected upon FUS downregulation (Figure 6A). Figure 6C shows 
qRT-PCR analysis on a selection of miRNAs derived from 6 
independent experiments with similar FUS depletion (70-80%): 
even if the effect on accumulation was in some case small (18% for 
miR-9, 20% for miR-125b and 25% for miR-132), the values were 
very reproducible in the different experiments. Other species, not 
restricted to neuronal cells, were more affected, such as miR-192, 
miR-199a and miR-628-5p that decreased to approximately 50% of 
control value. In contrast, miR-15a and miR-432 levels were 
unaffected and they have been utilized as controls in the following 
experiments. Notably, several of the down-regulated miRNAs (such 
as the neuronal miR-9, miR-125b and miR-132) displayed altered 
expression even when FUS levels were decreased to only 45% (data 
not shown), indicating that even half the levels of FUS are sufficient 
to affect the accumulation of specific miRNAs. 
The effects of FUS downregulation were also tested in HeLa cells, 
where RNAi provided 85% reduction (Figure 7A). Notably high-
throughput analysis using a Taqman array real time PCR revealed 
that in HeLa cells a lower proportion of miRNA species were 
negatively affected with respect to neuronal cells (Figure 7B). In 
order to test the accumulation of neuronal specific miRNAs, 
expression cassettes under the control of the ubiquitous U1 snRNA 
promoter were produced and individually transfected. Figure 7C 
indicates that the accumulation of the neuronal-specific miRNAs is 
affected similarly to neuronal cells and in some cases at a higher 
level (miR-212 and miR-132). Similarly to SK-N-BE cells, the 
miR-15a and miR-432 endogenous controls were unaffected. These 
results indicate that FUS regulates specific miRNA levels 
independently from their promoters, acting at some post-
transcriptional step in miRNA biogenesis.  
 
3.2 - FUS binds specific pri-miRNA transcripts 
A lot of factors that influences miRNA biogenesis are able to bind 
directly to pri-miRNAs molecules. To clarify in which way FUS is 
able to participate in miRNA biogenesis, I first tested the ability of 
FUS to bind to specific pri-miRNA molecules. 
Dottorato di ricerca in Genetica e Biologia Molecolare 
 
Pag 43  
 
   
R
el
at
iv
e 
q
u
a
n
ti
ty
 
  
miRNA 
U1 prom 3’ BOX 
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
A 
FUS 
GAPDH 
Drosha 
DGCR8 
siScr   siFUS 
siScr siFUS   
 
 
 
C 
B 
Figure 7. Knockdown of FUS in HeLa cells. (A) HeLa cells were treated 
with anti-FUS siRNA (siFUS) or with control siRNA (siScr). Levels of FUS, 
Drosha and DGCR8 were analyzed by Western blot. GAPDH was used as a 
loading control. (B) miRNA profiling in HeLa cells treated as in (A). Pie 
charts and table show the percentage of miRNA derelegulated more than 15%. 
(C) Plasmid constructs carrying different pri-miRNA sequences under the 
control regions of the U1snRNA gene were transfected in HeLa cells treated 
as in (A). Expression levels of mature microRNAs were analyzed by Northern 
blot (miR-9-2, miR-124 and miR-125b-2) or by qRT-PCR (miR-132, miR-
212, miR-15a and miR-432). For miR-15a and miR-432 the endogenous 
levels were measured. Error bars represent s.e.m. from 3 independent 
experiments. 
  
downregulated 53 30%
unaffected 59 34%
upregulated 62 36%
Total 174 100%
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Binding of a recombinant GST-FUS protein to different labelled 
pri-miRNAs was tested by band shift analysis in vitro. Figure 8A 
shows that those miRNAs affected by FUS depletion are also able 
to interact with it, maintaining a considerable amount of binding 
even in the presence of 250-fold excess of cold tRNA competitor. 
Notably, the control miR-15a, unaffected by FUS depletion, does 
not show any specific interaction. The only exception, among the 
tested miRNAs, was pri-miR-628 that, even if affected by FUS 
depletion, did not show, in our experimental conditions, any 
specific binding. Moreover, titration of FUS protein in an in vitro 
binding assay revealed that pri-miR-9-2/FUS interaction is 
concentration dependent (Figure 8B). 
Specificity of binding was also analyzed in extracts of SK-N-BE 
cells loaded on streptavidin columns pre-bound with in vitro 
transcribed biotinylated pri-miR-9-2 or pri-miR-15a. Figure 8C 
shows that FUS is strongly enriched in the bound fraction of pri-
miR-9-2 at difference with pri-miR-15a.  
Previous analyses on several pri-miRNA binding proteins indicated 
that the highly conserved terminal loops can act as platforms for 
trans-acting factors (Michlewski et al., 2008 and 2010). In this 
regard, sequence comparison of the loops of the affected miRNAs 
did not show any obvious consensus. However, since the miR-9-2 
loop contains a GU-rich sequence that was suggested to represent a 
FUS recognition element (Iko et al., 2004), I tested the effect of its 
mutation on FUS binding. The three G residues of the loop were 
substituted by C nucleotides and the resulting construct (miR-9-2 
mut) was tested for in vitro binding (Figure 9A). Such mutation 
produced a decrease of 50% in FUS interaction, indicating a 
consistent contribution of the terminal loop in binding specificity. 
However, it is possible that the stem provides the remaining binding 
specificity, as shown by FUS global RNA targets analysis (Hoell et 
al., 2011). A similar feature was also demonstrated for HnRNP A1 
where two binding regions were found: a primary one 
corresponding to the terminal loop of pri-miR-18a and a secondary 
site at the bottom of the stem (Michlewski et al., 2008). Moreover, 
the existence of different apparently disparate binding motifs of 
FUS has been already observed and suggested to be due to multiple  
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Figure 8. FUS binds in vitro specific pri-miRNA transcripts. (A) Band 
shift assays with recombinant GST-FUS using in vitro 
32
P-labelled pri-
miRNAs in the presence of increasing amounts of cold tRNA competitor (50, 
100 and 250-fold molar excess). Mock samples with the GST peptide were 
used as control (lanes mock). The arrow points to the specific RNA-protein 
complex. (B) Band shift analysis with increasing amounts of GST-FUS (75, 
150 and 300 ng) using pri-miR-9-2. (C) Streptavidin-conjugated magnetic 
beads bound to biotinylated pri-miRNA transcripts were loaded with nuclear 
extract from SK-N-BE cells. The bound and unbound fractions were tested for 
FUS binding by Western analysis. GAPDH detection and beads-only (BO) 
samples were used as negative controls. 
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Figure 9. Mutations of FUS do not alter pri-miRNA and Drosha binding. 
(A) Schematic representation of pri-miR-9-2 wild type (WT) and the mutant 
derivative (mut). Right panel: band shift assay with GST peptide (Mock) or 
with 300 ng of wild type (FUS
WT
) or mutant (FUS
R521C
) GST-fusions using in 
vitro 
32
P-labelled pri-miR-9-2. (B) Left panel: schematic representation of the 
constructs expressing flagged version of FUS wild type and of its mutant 
derivatives (R521C and P525L). Right panel: nuclear extracts from stable SK-
N-BE cell lines expressing flagged FUS were immunoprecipitated and 
analyzed by Western blot for Drosha interaction (C) Pull down of GST-FUS 
incubated with SK-N-BE nuclear extracts treated (+) or not (-) with RNase A. 
c
c
c
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distinct nucleic acid-binding domains, which may function 
independently or in combination (Tan et al., 2012). 
 
3.3 - C-terminal mutations of FUS do not affect either 
miRNA or Drosha binding 
I next tested the RNA binding ability of the FUS
R521C
 mutant 
derivative, one of the most common mutation linked to the ALS 
pathology shown to provide a severe phenotype (Belzil et al., 2009; 
Kwiatkowski et al., 2009). Recombinant GST-FUS
R521C 
was tested 
for pri-miR-9-2 binding (Figure 9A). Interestingly, this derivative 
provided the same binding activity of the wild type protein both on 
pri-miR-9-2 (WT) and on its mutant derivative (mut), indicating that 
the C-terminal region is not involved in miRNA recognition (Figure 
9A).  
Mutations in the C-terminal region have been described to produce 
cytoplasmic delocalization of the protein (Chiò et al., 2009; 
Kwiatkowski et al., 2009; Vance et al., 2009; Dormann et al., 
2010). In fact, FUS
R521C 
as well as
 
FUS
P525L
, another common ALS-
associated mutation, were shown to delocalize in the cytoplasm in 
HeLa transfected cells (Dormann et al., 2010) as well as in post-
mortem motor neurons, where they form aggregates (Vance et al., 
2009; Kwiatkowski et al., 2009). 
In order to test FUS localization in our cellular system, stable clones 
of SK-N-BE cells, expressing recombinant FUS
R521C
 and FUS
P525L
 
fused to the Green Fluorescent Protein under a Doxycycline (Dox) 
inducible promoter, were generated. Each cell line contained also 
wild type FUS fused to the Red Fluorescent Protein (see schematic 
representation in Figure 10A). Figure 10B shows that both mutant 
proteins display altered cellular localization with respect to the WT 
form: EGFP-FUS
P525L
, which corresponds to a very severe and 
juvenile form of ALS, is highly delocalized in the cytoplasm three 
days after Dox induction and produces a large number of 
aggregates. On the contrary, the cytoplasmic delocalization of 
EGFP-FUS
R521C
, which is a more common mutation and correlates 
with an adult form of ALS, is less pronounced than EGFP-FUS
P525L
. 
Notably, neither EGFP-FUS
R521C 
nor EGFP-FUS
P525L
 affected the  
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Figure 10. Intracellular localization of wild type and mutated FUS 
proteins. (A) Schematic representation of the epB-Puro-TT-RFP-FUS
WT
, 
epB-Bsd-TT-EGFP-FUS
R521C
 and epB-Bsd-TT-EGFP-FUS
P525L
 constructs. 
Triangles indicate the 5’ and 3’ Terminal Repeats (TR) of the epiggyBac 
vector. (B) SK-N-BE cells were co-transfected with epB-Puro-TT-RFP-FUS
wt
 
and epB-Bsd-TT-EGFP-FUS
R521C
 (top panels) or with epB-Puro-TT-RFP-
FUS
wt
 and epB-Bsd-TT-EGFP-FUS
P525L
 (bottom panels), together with a 
plasmid encoding for the epiggyBac transposase. After selection, stably 
transfected cells were induced with Doxycyclin for 3 days. 
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cellular localization of the co-expressed RFP-FUS
WT
, which 
remained confined to the nucleus. 
Since FUS was described as a Drosha interactor, I next tested the 
ability of the two FUS mutants (FUS
R521C 
and FUS
P525L
), to form 
complexes with Drosha in SK-N-BE cells expressing FLAG-tagged 
FUS constructs (see schematic representation in Figure 9B). Co-IP 
experiments indicated that both Flag-FUS
R521C
 and Flag-FUS
P525L
 
are complexed with Drosha similarly to the wild type (Figure 9B). 
To further characterize the binding properties between FUS and 
Drosha, I performed a GST pull-down assay with or without RNAse 
treatment. The GST-Pull down assay demonstrated that FUS-
Drosha interaction is resistant to RNase treatment (Figure 9C).  
These data indicate that the C-terminal mutations of FUS do not 
affect either miRNA or Drosha binding. This, together with the 
finding that even 50% depletions of FUS alter miRNA biogenesis, 
suggests that the cytoplasmic delocalization observed with the 
FUS
R521C
 and FUS
P525L
 mutants could affect the cellular repertoire 
of miRNAs by decreasing the levels of the protein available in the 
nucleus.  
 
3.4 - Exogenous FUS rescues miRNA accumulation in 
RNAi-FUS treated cells 
I next checked to what extent wild type and mutant FUS proteins 
were able to rescue miRNA biogenesis in RNAi treated cells. SK-
N-BE cell lines, carrying integrated copies of wild type or mutant 
Flag-FUS cDNAs with an unrelated 3’UTR and under the control of 
Doxycycline (Dox), were utilized. Upon treatment with siRNAs 
specific for the FUS 3’UTR, efficient depletion of the endogenous 
FUS protein was observed and, upon Dox induction, exogenous 
Flag-FUS expression was obtained (Figure 11A).  
The experiments shown in Figure 11B indicate that miR-132, miR-9 
and miR-192 levels are decreased in cells treated with siRNA 
against the 3’UTR of FUS in the absence of Dox and are rescued 
upon activation of the exogenous wild type FUS. The results with 
the two FUS mutants are consistent with their delocalization  
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Figure 11. Exogenous FUS can rescue the effects of endogenous FUS 
depletion. (A) Western blot of samples from SK-N-BE cell lines carrying the 
constructs indicated in Figure 9B or a control construct (Ctrl). Cells were 
treated with siRNA against the 3’UTR of FUS (siFUS-3’) or control siRNA 
(siScr) for 6 days in retinoic acid and in absence (left panel) or presence (right 
panel) of Doxycycline. Exogenous FLAG-FUS expression was tested using 
Flag antibodies while GAPDH was used as control. (B) The histogram show 
the miRNA levels from cells treated as described in (A), analyzed by qRT-
PCR. Error bars represent s.e.m. from 3 independent measurements and the 
significance was assessed by Unpaired Student’s t-test (**P<0.01, 
***P<0.001). 
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phenotype: FUS
R521C
, which displays only a slight cytoplasmic 
delocalization, is able to rescue miRNAs at levels similar to control, 
while FUS
P525L
, which has a stronger delocalization phenotype, has 
a lower rescue activity. It is important to note that also FUS
P525L 
provides sufficient rescue activity since, due to the overexpression 
conditions utilized, considerable amount of protein is still present in 
the nucleus (see Figure 10B).  
In conclusion, these experiments demonstrate a direct involvement 
of FUS on miRNA biogenesis and again indicate a direct correlation 
with the amount of FUS localized in the nucleus. 
 
3.5 - FUS cooperates with co-transcriptional Drosha 
recruitment 
Since it has been shown that the microprocessor complex acts co-
transcriptionally (Morlando et al., 2008; Ballarino et al., 2009), I 
examined whether FUS is associated with the chromatin and 
whether it participates in Drosha recruitment. Chromatin 
immunoprecipitation (ChIP) assays were performed on chromatin 
from SK-N-BE cells treated with RA for 6 days.  
Figure 12 shows that FUS is bound to the chromatin of miR-9-2 and 
miR-125b-2 coding loci, and that this association is lost after RNase 
treatment. Therefore, localization of FUS on miRNA chromatin loci 
is dependent on RNA, consistent with Microprocessor mechanism 
of action. Upon RNAi-mediated downregulation (Figure 13A), FUS 
association to the chromatin was consistently reduced (Figure 13B, 
panels FUS). Moreover, specific association was found on those 
pri-miRNA loci for which specific FUS binding was identified, 
whereas very low levels were detected on the pri-miR-15a locus. 
These findings suggest that chromatin recruitment of FUS at 
specific miRNA loci occurs during transcription and that it requires 
binding to nascent pri-miRNAs.  
ChIP with Drosha antibodies indicated that this protein was present 
on all miRNA loci. Upon FUS depletion, even though Drosha 
cellular levels were unaffected (Figure 13A), its association was 
reduced on those miRNA loci where FUS-pri-miRNA interaction  
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Figure 12. FUS is associated to the chromatin. (A) Schematic 
representation of miR-9-2, miR-125b-2 and miR-15a gene organization. 
Arrows indicate the positions of the PCR primers used. (B) ChIP analysis 
with anti-FUS antibodies using chromatin of SK-N-BE cells treated with 
retinoic acid (RA) for 6 days (black bars). Before immunoprecipitation half of 
the sample was treated with RNase (grey bars). Co-amplifications were 
carried out with miRNA- and tRNA-specific primers. The histograms show 
the values of FUS immunoprecipitation on miRNA loci normalized for the 
tRNA signal and expressed as enrichment over background (IgG). Error bars 
represent s.e.m. from 3 independent experiments. 
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Figure 13. FUS affects co-transcriptional Drosha recruitment. SK-N-BE 
cells were treated with anti-FUS siRNA (siFUS) or control siRNA (siScr) and 
maintained in retinoic acid (RA) for 6 days. (A) Western blot analysis of FUS, 
Drosha and GAPDH. (B) ChIP analyses with antibodies against FUS, Drosha 
and Pol II. Co-amplifications were carried out with miRNA- (miR-9-2, miR-
125b-2, miR-132 and miR-15a) and chromosome IV intergenic region-
specific primers. The histograms show the IP values on miRNA loci 
normalized for the intergenic region and expressed as enrichment over 
background signals (IgG). Error bars represent s.e.m. from 3 independent 
experiments. 
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was found (Figure 13B, panels Drosha). Indees, Drosha recruitment 
was not affected in the case of miR-15a that neither binds FUS nor 
is affected by its depletion. The decrease of Drosha recruitment on 
FUS-dependent miRNA loci was not due to defects in transcription 
since no decrease in RNA polymerase II loading was detected 
(Figure 13B, panels RNAPII). Instead, a slight increase in RNA 
polymerase II recruitment was observed upon FUS depletion for 
both miR-9-2 and miR125b-2. In consideration of previous data on 
FUS affecting transcription, with both positive and negative effects 
(Wang et al., 2008; Tan et al., 2012), it cannot be excluded that the 
alterations of RNA polymerase II loading upon FUS depletion on 
miRNA loci could be due to a secondary effect of FUS on 
transcription elongation or polymerase release and recycling. 
These data allowed me to conclude that FUS interaction is required 
for efficient recruitment of Drosha at specific pri-miRNA loci at 
early stages of transcription. These data, together with the 
observation that the FUS-Drosha interaction does not require RNA, 
allow me to suggest that the binding of FUS to nascent pri-miRNA 
molecules cooperates with efficient subsequent Drosha recruitment 
at the same sites (Figure 14). 
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Figure 14. Model of FUS role in miRNAs biogenesis. My data allowed me 
to propose a model in which FUS participate in miRNA biogenesis by 
facilitating an efficient recruitment of Drosha at specific pri-miRNA sites. In 
particular FUS is able to recognize pri-miRNA transcripts when they are still 
associated with the chromatin at early stages of transcription. Since FUS-
Drosha interaction does not require RNA, I suggest that the binding of FUS to 
nascent pri-miRNA molecules cooperates with efficient subsequent Drosha 
recruitment at the same sites. 
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3.6 - FUS overexpression induces downregulation of 
the endogenous protein. 
Increased amount of FUS protein has been described in a class of 
ALS patients, and this increase seems to be toxic for the cell 
homeostasis. Indeed, also the overexpression of human wild type 
FUS protein in mice causes the development of an aggressive 
phenotype with pathological features seen in human ALS patients 
(Mitchell et al., 2013). For this reason, I analyzed the pathways that 
are activated by FUS overexpression. At first I analyzed the effect 
of FUS, ectopically overexpressed, on the endogenous protein, in 
order to understand if any regulative mechanism was activated. SK-
N-BE cells, carrying integrated copies of wild type RFP-FUS 
cDNA with an unrelated 3’UTR and under the control of 
Doxycycline (Dox), were utilized. Overexpression of RFP-FUS 
produced a strong accumulation of the cDNA-encoded form, 
alongside with a conspicuous reduction of the endogenous levels of 
FUS protein (Figure 15A). This suggested the existence of a 
feedback regulation exerted by the exogenous construct (devoid of 
introns and 3’UTR) on the expression of the endogenous FUS. I 
next analysed also the levels of endogenous FUS mRNA after 
induction of RFP-FUS construct. Intriguingly, also FUS mRNA was 
strongly downregulated (Figure 15B). These observations suggest 
that this regulative feedback influences some steps of the mRNA 
processing or stability and that the strong accumulation of the RFP-
FUS fused protein from a construct devoid of the 3’UTR suggests a 
possible role also of this region in FUS regulation.  
 
3.7 - FUS overexpression induces exon skipping in FUS 
pre-mRNA 
Recent observations by Lagier-Tourenne et al., (2012), revealed that 
FUS has the ability to bind its own pre-mRNA, as observed by 
CLIP-seq analysis. Interestingly, FUS binding sites are enriched in 
the 3’UTR and in the highly conserved region between exon 6 and 
exon 8 (Figure 16A). The high conservation of an intronic region 
suggests a functional role for this sequence. By band-shift analysis I  
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Figure 15. FUS overxpression induces the doenregulation of endogenous 
FUS. (A) Western blot analysis with FUS antibodies on total proteins 
extracted from SK-N-BE cells, carrying a RFP control construct (Ctrl) or the 
RFP-FUS expression cassette (as in Figure 10A, epB-Puro-TT-RFP-FUS
WT
), 
grown for 48 hours in absence (-) or presence (+) of doxycycline (Dox). 
GAPDH was used as a loading control (left panel). A densitometric analysis 
of the endogenous FUS protein quantification is also shown (right panel). (B) 
Levels of endogenous FUS mRNA measured by qRT-PCR in cells treated as 
in (A). GAPDH mRNA was used as a loading control Error bars represent 
s.e.m. from 3 independent measurements and the significance was assessed by 
Unpaired Student’s t-test (*P<0.05; **P<0.01). 
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Figure 16. FUS binds directly exon 7 and 3’UTR of its own transcript. (A) 
Clip-Seq data from Lagier-Tourenne et al. (2012) showing the binding 
capacity of FUS on its own pre-mRNA. (B) Two isoforms annotated for FUS 
gene from Ensembl database. (C) Band-shift assay using in vitro 
32
P-labelled 
transcripts with either GST or GST-FUS recombinant proteins. Exon 7 and 
flanking regions, and the 3’UTR transcripts were used for the assay. Exon 14 
and flanking regions transcript was used as a negative control. The arrow 
points to the specific RNA-protein complex.  
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checked the ability of a recombinant GST-FUS protein to bind 
directly the 3’UTR of FUS and the exon 7 including the flanking 
sequences. Interestingly, FUS is able to bind directly both the exon 
7 and the 3’UTR of FUS in vitro, but not the exon 14, used as 
negative control. Therefore, FUS binds directly to this conserved 
region, and probably is able to participate in regulatory feedback by 
taking part in the splicing of its own pre-mRNA. 
Interestingly, among the different isoforms annotated in Ensembl 
database, beyond the 15-exons protein-coding one (FUS-001), there 
is an isoform lacking exon 7 (FUS-010; Figure 16B). This isoform 
is predicted to be degraded by nonsense-mediated decay because of 
the formation of a premature stop codon. Therefore, I tested 
whether FUS overexpression could affect the splicing of its own 
pre-mRNA. RFP-FUS fusion protein (the same constructs used in 
Figure 15A) was overexpressed in SK-N-BE cells. Through qRT-
PCR using specific oligonucleotides that are able to recognize only 
the isoform lacking of exon 7 (Figure 17A), I observed that FUS 
overexpression induced a strong increase of the amount of this 
isoform (Figure 17B). Then, I measured the levels of the isoform 
lacking exon 7 in SK-N-BE cells depleted of FUS through RNAi 
(Figure 17C) and I observed a 90% decrease of this isoform. 
Notably, this decrease was stronger than the decrease measured for 
the total amount of FUS mRNA, due to RNAi (Figure 17C). 
Altogether these data describe a feed-forward feedback, in which 
the overexpression of FUS induces the skipping of exon 7 from the 
endogenous FUS pre-mRNA, producing an out-of-frame mRNA 
unable to make a functional protein, thus ensuring the correct level 
of the FUS protein (Figure 22). 
 
3.8 - The 3’UTR of FUS has an important role for FUS 
regulation, altered by G48A mutation 
To test whether in the FUS autoregulatory control also the 3’UTR is 
involved, I started with the characterization of this region. 3’RACE 
assay allowed the mapping of the 3’ end of the FUS mRNA isoform 
expressed in SK-N-BE cells 164 nucleotides downstream of the 
termination codon (Figure 18A). To test the impact of the 3’UTR of  
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Figure 17. (A) Schematic representation of the exon 6-exon 8 portion of the 
FUS pre-mRNA, together with the two spliced isoforms deriving from the 
alternative use of exon 7. The premature stop codon (PTC) and the position of 
the oligonucleotides (arrows) used for qRT-PCR are indicated. (B) The 
histogram shows the levels of the exon 7 skipping measured by qRT-PCR in 
cells stably transfected and treated as in Figure 15A. (C) Western blot 
analysis with FUS antibodies of proteins from SK-N-BE cells treated with 
anti-FUS (siFUS) or control (siScr) siRNA. GAPDH was used as loading 
control. (D) The levels of all FUS isoforms (FUS tot) and exon 7 skipped 
mRNAs were measured by qRT-PCR in cells treated as in (C). Significance 
was assessed by Unpaired Student’s t-test (*P<0.05, **P<0.01). 
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Figure 18. (A) Agarose gel showing the results of the 3’RACE assay 
performed on RNA from SK-N-BE cells. Part of the DNA sequence 
corresponding to the gel band is shown together with the underlined 
polyadenylation site (PAS) and a schematic representation of the FUS open 
reading frame (ORF) and 3’UTR. (B) FUS cDNA constructs used; FUS-WT, 
contains the wild-type 3’UTR, while the mutant derivatives contain the G48A 
substitution (FUS-G48A) or the deletion of the entire 3’UTR (FUS-3’UTR). 
Histograms show the levels of FUS protein (left panel) and mRNA (right 
panel) obtained from SK-N-BE cells transfected with the different FUS 
constructs. FUS mRNA levels were normalised on the neomycin marker co-
expressed from the same plasmid.  
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FUS on protein accumulation I prepared different plasmids 
containing FUS cDNA with or without the 3’UTR (FUS-WT and 
FUS-3’UTR). Transfection of these plasmids in SK-N-BE cells, 
resulted in a strong accumulation of the FUS protein and mRNA 
derived from the constructs lacking of the 3’UTR (Figure 18B).  
Bioinformatic research for miRNA responsive elements (MREs) in 
the FUS 3’UTR, revealed that in this region there is a predicted 
conserved binding site for miR-141 and miR-200a. These two 
miRNAs share the same seed sequence and belong to the same 
miRNA family. Interestingly, among the identified 3’UTR 
mutations associated to ALS (Sabatelli et al., 2013; Figure 2A), two 
patients carried the G48A substitution (in one case of inherited 
type) that localizes the predicted binding site for miR-141 and miR-
200a.  
When the G48A mutation was tested in the context of a cDNA 
construct (FUS-G48A), the levels of FUS, as well as of its mRNA, 
were reproducibly higher with respect to those raised from the wild 
type construct (Figure 18B), indicating the contribution of this 
mutation on the control of FUS accumulation. Notably, the increase 
did not reach the levels observed with FUS-3’UTR, suggesting the 
presence in the 3’UTR of additional regulatory elements important 
for controlling the homeostatic levels of FUS. This is in line with 
the observation that three other 3’UTR mutations, associated to 
severe ALS, are linked to high accumulation of the FUS protein 
(Sabatelli et al., 2013). However, none of these additional mutations 
appears to affect putative conserved miRNA binding sites, 
according to TargetScan and PicTar analysis.  
 
3.9 - miR-141 and miR-200a target FUS mRNA, but 
not the G48A mutant derivative 
In order to test if FUS is a real target of miR-141 and miR-200a, I 
performed a canonical luciferase assay. Furthermore, I checked also 
if the G48A mutation, associated with ALS, affects the miRNA-
mediated repression. 
Luciferase reporters harboring the 3’UTR of FUS (Luc-FUS-WT) or 
the deletion of the miR-141/200a seed site (Luc-FUS-seed) or the  
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Figure 19. (A) Luciferase fusion constructs. (B) Seed sequence of miR-141 
and miR-200a (miR-141/200a WT) and of their mutant derivatives (miR-
141/200a mut) containing the complementary substitution to the G48A 
mutation. (C) Relative luciferase levels of Luc-FUS-WT, Luc-FUS-seed and 
Luc-FUS-G48A constructs co-transfected in SK-N-BE cells with en empty 
vector (Ctrl) or with miRNA (miR-141 or miR-200a) expressing plasmids. 
(D) Histograms indicate the relative luciferase activity of the Luc-FUS-G48A 
construct co-transfected in SK-N-BE cells with wild type (WT) or mutant 
(mut) miRNA expressing plasmids. Data were derived from three independent 
experiments; error bars represent s.e.m., significance was assessed by 
Unpaired Student’s t-test (*P<0.05, **P<0.01). 
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G48A point mutation (Luc-FUS-G48A) were individually co-
transfected in SK-N-BE cells with miR-141 and miR-200a 
expressing plasmids or with a control plasmid (Ctrl) (Figure 19A). 
Luciferase levels of Luc-FUS-WT were significantly reduced with 
each one of the two miRNAs, whereas Luc-FUS-seed lacked this 
effect (Figure 19C). Notably, the Luc-FUS-G48A construct, 
containing the G48A point mutation, was also insensitive to miR-
141 or miR-200a repression (Figure 19C). Therefore, in patients 
with G48A mutations the regulation mediated by miR-141 and 
miR-200a might not succeed. 
However, co-transfection of Luc-FUS-G48A with plasmid 
expressing miR-141 or miR-200a derivatives, containing a 
nucleotide substitution complementary to the G48A mutation (miR-
141/200a mut), resulted in rescue of miRNA-dependent repression 
(Figure 19D). These data indicate the specificity of the G to A 
substitution for miR-141/200a recognition and function. Therefore, 
in ALS patients carrying G48A mutation the increased levels of the 
FUS protein might not be lowered by the action of miR-141/200a. 
 
3.10 - FUS induces the expression of miR-141 and 
miR-200a 
Since FUS, a well described Drosha interactor, was previously 
shown to enhance miRNA expression by direct binding to nascent 
pri-miRNAs on the chromatin and facilitating co-transcriptional 
processing, I tested these features on miR-141 and miR-200a. SK-
N-BE cells, carrying integrated copies of wild type FRP-FUS 
cDNA under the control of Doxycycline (Dox), were utilized. 
Notably, upon FUS overexpression in SK-N-BE cells, the levels of 
miR-141 and miR-200a strongly increased (Figure 20). MiR-15a 
and miR-432 levels, previously shown to be unaffected by FUS 
modulation, did not change after FUS overexpression. To 
recapitulate the mechanisms of action of FUS on these two 
miRNAs, the binding of a recombinant GST-FUS protein to 
labelled pri-miRNAs was tested in vitro. By band-shift assay, I 
observed that FUS is able bind directly and specifically to both pri- 
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Figure 20. FUS overexpression induces miR-141 and miR-200a 
upregulation. Levels of miR-141 and miR-200a measured by qRT-PCR in 
SK-N-BE cells, carrying a RFP control construct (Ctrl) or the RFP-FUS 
expression cassette, grown for 48 hours in absence (-) or presence (+) of 
doxycycline (Dox). miR-15a and miR-432 were used as controls. Data were 
derived from at least three independent experiments; error bars represents 
s.e.m., significance was assessed by Unpaired Student’s t-test (*P<0.05). 
Stefano Dini Modigliani 
 
 
Pag 66  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A 
pri-miR-9-2 pri-miR-15a pri-miR-141 pri-miR-200a 
0
5
10
15
F
o
ld
 o
v
er
 b
ac
k
g
ro
u
n
d
 
FUS ChIP 
miR-200a 
miR-15a 
 
 
miR-141 
 
B 
Figure 21. (A) Gel mobility shift assay using the indicated in vitro 
32
P-
labelled pri-miRNA transcripts with either GST or GST-FUS recombinant 
proteins. The arrow points to the specific RNA-protein complexes. (B) ChIP 
analysis with FUS-antibodies on chromatin from SK-N-BE cells expressing 
Dox-inducible flag-FUS cDNA. Genomic regions coding for miR-15a, miR-
141 and miR-200a were analyzed. Co-amplifications were carried out with 
primers specific for miRNA and chromosome IV intergenic region. The 
histograms show the IP values on miRNA loci normalized for the intergenic 
region and expressed as enrichment over background signals (IgG). Error bars 
represent standard error from 3 independent experiments.  
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miR-141 and pri-miR-200a (Figure 21A). No binding was instead 
observed when control pri-miR-15a was used. According to our 
previous data indicating the chromatin localization of FUS, ChIP 
experiments with anti-FUS antibodies revealed a specific 
localization of FUS on the chromosomal loci encoding for miR-141 
and miR-200a, while no localization was detected on the negative 
control, miR-15a (Figure 21B).  
In conclusion, these data provide evidence for the existence of a 
feed forward regulatory loop in which FUS controls the expression 
levels of two miRNAs, which in turn regulate FUS accumulation 
(Figure 22). Interestingly, the disruption of this circuitry correlates 
with a mutation that establishes an ALS phenotype: whether the 
pathogenesis of the disease is due to the increased FUS levels or to 
the subsequent up-regulation of specific classes of miRNAs remains 
an interesting question to be addressed.  
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Figure 22. Model of FUS autoregolatory mechanisms. Left panel: 
increased levels of FUS are able to induce the skipping of exon 7 of its own 
pre-mRNA. This event leads to the formation of an isoform that is predicted 
to be degraded by non-sense mediated decay for the formation of a premature 
stop codon. Right panel: increased levels of FUS are able to induce the 
expression of miR-141 and miR-200a, that are able to target and repress FUS 
mRNA. These two mechanisms are able to restore the correct levels of FUS 
when they are increased. The alteration of part of these regulatory 
mechanisms can lead to ALS onset. 
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4 - DISCUSSION 
FUS is a multifunctional nuclear protein, involved in RNA 
metabolism, which has been recently linked to familial forms of 
ALS, a severe age-dependent disorder causing degeneration of 
motoneurons in the brain and spinal cord. Since mutations seem to 
mainly affect the nucleus/cytoplasmic distribution of the protein, it 
has been suggested that these mutations may have a dual effect: i) 
loss of function in the nucleus and ii) toxic gain of function in the 
cytoplasm. Therefore, dosage alteration of the protein in the two 
compartments can provide a hint for understanding ALS pathology. 
FUS has been attributed a large number of functions in the nucleus 
mainly related to transcription and RNA processing, whereas 
cytoplasmic aggregated forms have been suggested to cause 
alteration in neuronal plasticity, or in nuclear RNA maturation and 
transport (Belly et al., 2005; Polymenidou et al., 2012).  
Among the large repertoire of nuclear functions, I focused on the 
observation that FUS was described as a Drosha interactor (Gregory 
et al., 2004). Here I demonstrated that the FUS protein has a dual 
function of interacting with specific pri-miRNA sequences and with 
Drosha. Moreover, I show that FUS binds to nascent pri-miRNA 
molecules and helps Drosha recruitment on the chromatin allowing 
efficient miRNA processing.  
I also show that, among the others, FUS affects the biogenesis of 
miRNAs with a relevant role in neuronal function, differentiation 
and synaptogenesis such as miR-9, miR-125b and miR-132 (Laneve 
et al., 2007 and 2010; Packer et al., 2008; Edbauer et al., 2010; 
Pathania et al., 2012).  
Notably, I observed that the accumulation levels of these miRNAs 
were lowered even when the residual amount of FUS was only half 
with respect to control. These data could explain why mutations 
affecting FUS nuclear dosage could have a remarkable negative 
effect on miRNA homeostasis, thus providing a possible correlation 
with the ALS pathogenesis. Due to the fact that ubiquitous miRNAs 
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are affected by FUS downregulation, one should envisage a more 
general toxic effect not restricted to the nervous system. However, 
several considerations could explain a higher susceptibility of 
neuronal cells: i) the miRNA downregulation is limited and only 
neuronal cells could be affected by such tiny changes; ii) the 
neuronal miRNA species identified play non-redundant essential 
functions; iii) protein delocalization and aggregate formation could 
be partially compensated in proliferating cells, while in post-mitotic 
neuronal cells these processes would have additive effects. The 
progressive accumulation and aggregation is indeed a phenomenon 
common to other neurodegenerative diseases due to proteins having 
the ability of forming amyloid-like fibers (Yamamoto et al., 2011; 
Han et al., 2012).  
It is important to underline that FUS plays multiple roles in the 
nucleus and in particular during transcription. ChIP and promoter 
microarrays have identified a large number of target genes regulated 
by this factor (Tan et al., 2012), thus indicating that miRNA 
biogenesis may represent only part of FUS activity.  
It is well documented that FUS levels are crucial for the cell 
homeostasis. On one side, decreased levels of FUS protein in the 
nucleus has been described in ALS patients, and in FUS-null mice 
have been observed chromosomal instability and neurons with 
abnormal spine morphology (Hicks et al., 2000; Fuji et al., 2005). 
On the other side also increased amount of FUS protein has been 
described in ALS patients, and mice overexpressing wild-type 
human FUS develop an aggressive phenotype with an early onset of 
several pathological features observed in human ALS patients 
(Mitchell et al., 2013). Notably, have been identified mutations in 
the 3’UTR of FUS in ALS patients, in which a strong increase of 
FUS protein was described (Sabatelli et al., 2013). Even though in 
these patients the protein is wild type, ALS still occurs most 
probably for the failure of a regulatory mechanism. Here I 
demonstrated the existence of two feed forward regulatory loops in 
which FUS controls its own levels (Figure 22). On one side I show 
a regulatory mechanism in which FUS binds directly its own pre-
mRNA and induces skipping of exon 7. This event leads to the 
formation of an isoform with a premature stop codon that is 
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predicted to be degraded by nonsense-mediated decay. Therefore, in 
this case, in order to re-establish the correct amount of FUS, the 
surplus of the protein leads to the formation of an unfunctional 
RNA isoform. On the other side, I demonstrated that FUS induces 
the expression of two miRNAs (miR-141 and miR-200a), which in 
turn are able to regulate FUS accumulation. Interestingly, a 3’UTR 
mutation in the binding site for miR-141/200a (G48A) was found in 
two ALS patients. Therefore, the disruption of this circuitry might 
correlate with a mutation that establishes an ALS phenotype; 
however, whether the pathogenesis of the disease is due to the 
increased FUS levels or to the subsequent up-regulation of specific 
classes of miRNAs remains an interesting question to be addressed. 
Notably, the up-regulation of miR-200a was described in Alzheimer 
(Cogswell et al., 2008) and Huntington (Jin et al., 2012) 
neurodegenerative diseases; moreover, miR-200a predicted targets 
were implicated in regulating synaptic function, neurodevelopment, 
and neuronal survival, suggesting that deregulation of this miRNA, 
as a consequence of FUS mutation, might have a consistent impact 
on ALS pathogenesis. Finally, I show that the G48A mutation can 
be suppressed by ad hoc modified miRNAs suggesting the 
possibility of rescuing the correct FUS control and opening 
interesting perspectives in the treatment of this type of mutations.  
Due to the fact that the pathological effects of FUS mutations are 
mainly restricted to neuronal cells, it is possible that FUS thresholds 
become critical only in these cells, and that miRNAs are part of the 
molecular mechanisms whose deregulation may have a relevant role 
in ALS pathogenesis. 
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5 - MATERIALS AND METHODS 
Cell Cultures and Treatments. SK-N-BE cells were cultured in 
RPMI 1640 medium (Gibco), supplemented with 10% fetal bovine 
serum, 1-L-glutamine, and penicillin/streptomycin, and induced to 
differentiate by 10M all-trans-Retinoic acid (RA, Sigma). SK-N-
BE plasmid transfection was carried out using Lipofectamine and 
Plus Reagent (Invitrogen) according to the manufacturer’s 
instructions while siRNAs targeting FUS coding region (Hs_FUS_4 
FlexiTube siRNA, SI00070518, Qiagen) or 3’UTR (for sequence, 
see below) or control siRNA (AllStars Negative Control siRNA, 
Qiagen) were transfected using HiPerfect Transfection Reagent 
(Qiagen) according to the manufacturer’s instructions.  
For the generation of stable SK-N-BE cells expressing FUS protein, 
upon plasmid transfection (epB-Puro-TT derived plasmids and 
epiggyBac transposase vector) the cells were selected by Puromycin 
(1g/ml) treatment and the expression of the different forms of FUS 
protein was induced by adding Doxycycline (0,2g/ml) to the 
culture medium. 
For the rescue experiments stable SK-N-BE cells expressing FLAG-
FUS
wt
, FLAG- FUS
R521C
 and FLAG-FUS
P525L
 were treated with 
siRNA against the 3’UTR of FUS (siFUS-3’) for 6 days in RA. The 
last 2 days the cells were treated or not with Doxycycline 
(0,02g/ml final concentration). 
HeLa cells were cultured in D-MEM medium (Gibco), 
supplemented with 10% fetal bovine serum, 1-L-glutamine, and 
penicillin/streptomycin. HeLa plasmid and siRNA transfections 
were carried out using Lipofectamine 2000 (Invitrogen) according 
to the manufacturer’s instructions. 
 
Plasmid construction. To generate the constructs overexpressing 
miRNAs, the genomic fragments containing pri-miR-9-2, pri-miR-
124-2, pri-miR-212, pri-miR-132, pri-miR-141 were PCR amplified 
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(oligonucleotides sequences are listed below) and cloned using 
BglII and XhoI restriction sites of U1snRNA expression cassette 
(Denti et al., 2004). Plasmid overexpressing pri-mir-125b-2 is 
described in Laneve et al., 2007. Plasmid overexpressing pri-mir-
200a (mouse) was cloned by Francesca De Vito using BglII and 
XhoI restriction sites of U1snRNA expression cassette. The vectors 
were transfected in combination with a plasmid carrying a modified 
snRNA U1 gene (U1#23; Denti et al., 2006) to measure the 
efficiency of transfection.  
The mutant plasmids overexpressing miR-141mut and miR-
200amut were obtained by double inverse PCR amplification on the 
previous cloned plasmids, in order to obtain the single point 
mutation of the mature miRNAs and the complementary 
substitution for rescuing a correct structure for the efficient 
processing. 
For generating GST fused FUS protein, FUS cDNA was PCR 
amplified from vector pCMV6-AC (SC320263, OriGene 
Technologies) with the oligolucleotides FUS FW and FUS REV and 
inserted in BamHI and XhoI restriction sites of pGEX-4T-1 
(Amersham Biosciences) raising FUSWT vectors. The mutant form 
FUSR521C was obtained by inverse PCR amplification on FUSWT 
vectors using the oligonucleotides FUS R521C FW and FUS R521C 
RV. 
For the generation of the transposable element vectors for inducible 
expression of FUS, cDNA from vector pCMV6-AC was amplified 
using the Flag-FUS FW, FUS WT RV, FUS R521C RV and FUS 
P525L RV and inserted into the epB-Puro-TT vector generating the 
Flag-FUSWT, Flag-FUSR521C and Flag-FUSP525L plasmids. The 
transposable element vectors for inducible expression of RFP-
FUSwt and EGFP-FUSR521C and EGFP-FUSP525L were derived from 
the enhanced piggyBac (ePiggyBac) vector epB-Bsd-TRE described 
in Rosa et al. (2011). Briefly, a cassette encoding for the rtTA-
Advanced protein (Clontech) was fused to the Puromycin or 
Blasticidin resistance coding sequences through a T2A self-cleavage 
peptide element, and put under the control of the ubiquitous pUbc 
promoter in the epB-Bsd-TRE vector. The resulting plasmids (epB-
Puro-TT and epB-Bsd-TT) hold on the opposite direction the 
tetracycline-responsive promoter element (TRE), followed by a 
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short multicloning site. Therefore both elements of the TET-ON 
system are present in the same vector. The RFP and EGFP coding 
sequences, devoid of the stop codon, were then inserted in the epB-
Puro-TT and epB-Bsd-TT plasmids, respectively, generating the 
epB-Puro-TT-RFP and epB-Bsd-TT-EGFP. Finally, the coding 
sequences of FUS, wild type or mutated, were cloned in frame with 
the fluorescent proteins, generating the epB-Puro-TT-RFP-FUSwt, 
epB-Bsd-TT-EGFP- FUSR521C and epB-Bsd-TT-EGFP- FUSP525L. 
The FUS-G48A mutant construct was obtained by inverse PCR 
amplification on FUS-WT plasmid (SC320263, OriGene 
Technologies) using the oligonucleotides FUS-G48A FW and RV 
while the FUS-3’UTR mutant construct was generated by PCR 
amplification on FUS-WT plasmid using the oligonuclotides FUS-
3’UTR FW and RV. 
To generate the constructs for the luciferase assay Luc-FUS-WT, the 
genomic fragment containing the 3’UTR was PCR amplified using 
the oligonucleotides FUS-3UTR NotI FW and FUS-3UTR NotI RV 
and cloned downstream the Renilla Luciferase open reading frame 
in psiCHECK2 vector (Promega) using NotI restriction sites. The 
mutant derivatives Luc-FUS-seed and Luc-FUS-G48A were 
obtained by inverse PCR amplification using the oligonucleotides 
FUS 3'UTR seed FW and RV, and FUS-G48A FW and RV 
respectively. For the rescue experiment a 164 nt long 3’UTR 
carrying the G48A substitution was used. This was generated by 
inverse PCR amplification on Luc-FUS-G48A construct using the 
FUS-G48Ashort FW and RV oligonucleotides. 
 
Protein extraction and Western blot. Whole-cell protein extracts 
were prepared from SK-N-BE and HeLa cells lysed in RIPA buffer. 
Extracts were separated by electrophoresis on 4–12% poly-
acrylamide gel (Invitrogen) and electroblotted onto nitrocellulose 
membrane (Protran, S&S, Drammen, Norway). The immunoblots 
were incubated with the following antibodies: anti-FUS/TLS (sc-
47711, Santa Cruz), anti-DGCR8 (ab90579, Abcam), anti-Drosha 
(ab12286, Abcam), anti-N-Myc (sc-56729, Santa Cruz), anti-
FlagM2 (Sigma), anti-GAPDH (sc-32233, Santa Cruz) as a loading 
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control. The densitometric analysis was performed using Image Lab 
software (Bio-Rad). 
 
Luciferase assay. Luc-FUS-WT, Luc-FUS-seed and Luc-FUS-
G48A plasmids were co-transfected with the plasmids expressing 
miR-141/200a and their mutant derivatives in SK-N-BE cells. After 
48 hours of incubation cells were assayed with the Dual-Luciferase 
Assay (Promega). 
 
RNA preparation and analysis. Total RNA was isolated using 
miRNeasy Mini Kit according to the manufacturer’s instructions 
(Qiagen). 
For the Northern blot assay 5g of total RNA were fractionated on 
10% poly-acrylamide gel in MOPS–NaOH (pH 7), 7 M Urea and 
transferred onto Amersham Hybond-NX nylon membrane (GE 
Healthcare). RNA cross-linking was performed in 0.16 M N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride and 
0.13 M 1-methylimidazole (Sigma-Aldrich) at pH 8, for 2 hours at 
60°C. DNA oligonucleotides complementary to the sequence of 
mature miR-9, miR-124, miR-125b, miR-132, U1#23 and to 5.8S-
rRNA were 32P-labeled and used as probes. Densitometric analysis 
was performed using Typhoon Imager (GE Healthcare) and 
ImageQuant software (Molecular Dynamics).  
 
Quantitative RT- PCR analysis. cDNA generation was carried out 
using the miScript Reverse Transcription Kit (Qiagen). The Real-
time PCR detection of miRNAs was performed using miScript 
SYBR-Green PCR Kit and DNA oligonucleotides by Qiagen, on a 
7500 Fast Real-Time PCR (Applied Biosystem). The values 
obtained were normalized for snoRNA-U25. The qPCR detection of 
mRNAs was performed using the oligonucleotides listed below. For 
the detection of the skipping of exon 7 were used oligonucleotides 
specific for the isoform lacking the exon 7 (FUS exon 6 FW and 
FUS exon 6-8 REV). GAPDH was used as a loading control. The 
values were analyzed by the unpaired Student’s t-test. P-values were 
calculated for samples from 3 independent experiments unless 
otherwise indicated.  
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miRNAs high-throughput analysis. 700ng of total RNA extracted 
from SK-N-BE cells were retrotranscribed using the TaqMan 
MicroRNA RT Kit (Applied Biosystems). The Real-time detection 
of the miRNA levels was performed using the TaqMan® Human 
MicroRNA Array A (Applied Biosystems) according to the 
manufacturer’s instructions. The values obtained were normalized 
for snoRNA-U44. 
 
Band-shift. Band-shift assays were carried out as previously 
described (Song et al., 2012) with minor modifications. Purified in 
vitro labelled transcripts were incubated with 6 nmoles of 
recombinant GST or GST-FUS proteins in the presence of 
increasing amount of cold tRNA competitor, from 50 to 250 molar 
excess. The complexes were separated by a 4% acrylamide non-
denaturing gel. Densitometric analysis was performed using 
Typhoon Imager (GE Healthcare) and ImageQuant software. 
 
Chromatin immunoprecipitation assay. ChIP analyses were 
performed on chromatin extracts from SK-N-BE cells according to 
manufacturer’s specifications of MAGnify Chromatin 
Immunoprecipitation System kit (Invitrogen). Sheared Chromatin 
was immunoprecipitated with the following antibodies: anti-
FUS/TLS (sc-47711, Santa Cruz), anti-Drosha (ab12286, Abcam), 
anti-Pol II (sc-889, Santa Cruz). The occupancy of the 
immunoprecipitated factor on miRNA loci was estimated by 
normalizing for the occupancy on tRNA coding region or 
chromosome IV intergenic region and expressed as enrichment over 
background (IgG). Densitometric analysis was performed using 
Typhoon Imager (GE Healthcare) and ImageQuant software 
(Molecular Dynamics). RNase treatment of the chromatin and the 
occupancy of the immunoprecipitated factor on miRNA loci were 
carried out as described in Morlando et al., 2008. Oligonucleotide 
used for PCR amplifications are listed below.  
 
Biotin pull-down. Binding of biotinylated transcripts to 
paramagnetic streptavidin Dynabeads (Dynal) and incubation with 
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nuclear lysate was carried out as described in Figueroa et al., 2003. 
Biotilylated transcripts were obtained from PCR generated 
templates (oligonucleotides are listed below) using 0.35mM Biotin-
16-UTP (Roche) as described previously (Dye & Proudfoot, 1999). 
 
GST-FUS Purification FUSWT and FUSR521C were transfected in 
BL21 cells and induced with 0,5mM IPTG for 4h at 28°C. Cell 
pellets were resuspended in 5 ml of NET-N buffer (Tris-HCl pH 8 
20mM, NaCl 100mM, NP-40 0.5%, EDTA 0,5mM) supplemented 
with a cocktail of protease inhibitor (Roche). After sonication the 
supernatant fractions were loaded on to Glutathione-Agarose resin 
(G4510, Sigma) and incubated for 1 hour at 4°C and then washed 
once with NET-N buffer and twice with NET (Tris-HCl pH 8 
20mM, NaCl 100mM, EDTA 0,5mM). The recombinant GST-
proteins were eluted with the elution buffer containing 20mM L-
Gluthatione reduced and 100mM Tris-HCl pH 8. 
 
Co-immunoprecpitation and GST-Pull down. Co-
immunoprecipitation was perfomed using Immunoprecipitation kit - 
Dynabeads Protein G (Invitrogen) according to the manufacturer’s 
instructions. To obtain the nuclear extracts, the cell pellets were 
resuspended with Buffer A (Tris-HCl pH 8 20mM, NaCl 10mM, 
MgCl2 3mM, Igepal 0,1%, glycerol 10%, EDTA 0,2mM) 
supplemented with protease inhibitor (Roche) and after 
centrifugation the nuclei were resuspended in Buffer C (Tris-HCl 
pH 8 20mM, NaCl 400mM, glycerol 20%, DTT 1mM) 
supplemented with protease inhibitor (Roche). After three cycles of 
incubation in liquid nitrogen followed by incubation at 37°C the 
nuclear extract was recovered by centrifugation. 
The GST-Pull down experiments were carried out as described in 
Morlando et al., 2004 with minor modification. 50g of SK-N-BE 
nuclear extract were used instead of in vitro translated Drosha 
protein and the RNase treatment was carried out with RNase A 
(Sigma) at 20mg/ml final concentration. 
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Oligonucleotides used in this study: 
 
Oligonucleotides used for cloning:  
miR-9-2 -400 FW BglII 5′-GCCAGATCTAGGCTAAAGAGTCTT-3′ 
miR-9-2 +400 RV XhoI 5′-GCCCTCGAGGGTGCCTCCCAAAGG-3′ 
miR-124 -50 BglII FW 5′-CCGAGATCTGGTAATCGCAGTGGGTCTTA 
TAC-3′ 
miR-124 +50 XhoI RV 5′-CCGCTCGAGCTGACCCTGAGATGCTTTG 
GTG-3′ 
miR-212-132 BglII FW 5′-GGCAGATCTCTCTGCGAGCGGAGCTGTC 
CTC-3′ 
miR-212-132 XhoI RV 5′-GCGCTCGAGCCTCGGTGGACTCAGCCG-3′ 
miR-141 BglII FW 5'-ACTAGATCTCCCACCCAGTGCGATTTGTC-3' 
miR-141 XhoI RV 5'-TCACTCGAGAACCAGTGTTTCCACATCT 
TGC-3' 
miR-141 mut FW 5'-TTGTCTGGTAAAGATGGCTCCC-3' 
miR-141 mut RV 5'-TGTTAGGAGCTTCACAATTAGACC-3' 
miR-141 star mut FW 5'-ATGTTGGATGGTCTAATTGTGAAG-3' 
miR-141 star mut RV 5'-TGTACTGGAAGATGGACCCAGG-3' 
miR-200a BglII FW 5'-GGAAGATCTTATTGCGATGCATATACGGT 
CTC-3' 
miR-200a XhoI RV 5'-ATTCTCGAGCTGTAGAGCTGAGACAGGC 
CCT-3' 
miR-200a mut FW 5'-TTGTCTGGTAACGATGTTCAAAG-3' 
miR-200a mut RV 5'-TGTTAGAGTCAAGCCAAGAAATC-3' 
miR-200a star mut FW 5'-ATGCTGGATTTCTTGGCTTGAC-3' 
miR-200a star mut RV 5'-TGTCCGGTAAGATGCCCAC-3' 
FUS 3'UTR NotI FW 5'-ATTGCGGCCGCTTAGCCTGGCTCCCCAGG 
TTC-3' 
FUS 3'UTR NotI RV 5'-ATTGCGGCCGCGTTTAATCTCTGCTCTCA
 AGG-3' 
FUS 3'UTR seed FW 5'-CCCTCGTTATTTTGTAACCTTC-3' 
FUS 3'UTR seed RV 5'-GGTACAGGACAAAAAGCTGTTC-3' 
FUS G48A FW 5'-ATGTTACCCTCGTTATTTTGTAAC-3' 
FUS G48A RV 5'-TGGGTACAGGACAAAAAGCT-3' 
FUS-3'UTR FW 5'-GCCGCATCCATGGACTACAAGGACGACGAT 
GACAAGATGGCCTCAAACGATTATACC-3' 
FUS-3'UTR RV 5'-GCCGCGGCCGCTTAATACGGCCTCTCCCTGC 
GATCC-3' 
FUS-G48Ashort FW 5'-AACTAAAATGGTCACTTTTAATGG-3' 
FUS-G48Ashort RV 5'-GAGCGGCCGCTGGCCGCAATA-3' 
  
Oligonucleotides used for GST-FUS cloning:  
FUS BamHI FW 5′-GCCGGATCCATGGCCTCAAACGATTATACC-3′ 
FUS XhoI RV 5′-GCCCTCGAGTTAATACGGCCTCTCCCTGCG-3′ 
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FUS R521C FW 5′-TGCAGGGAGAGGCCGTATTAACTC-3′ 
FUS R521C RV 5′-ATCCTGTCTGTGCTCACCCCTG-3′ 
  
Oligonucleotides used for Flag-FUS cloning:  
Flag FUS FW 5′-GCCGGATCCATGGACTACAAGGACGACG 
 ATGACAAGATGGCCTCAAACGATTATACC-3′ 
FUS WT RV 5′-GCCAAGCTTTTAATACGGCCTCTCCCTGCGATCC-3′ 
FUS R521C RV 5′-GCCAAGCTTTTAATACGGCCTCTCCCTGCAATCC-3′ 
FUS P525L RV 5′-GCCAAGCTTTTAATACAGCCTCTCCCTGCGATCC-3′ 
 
Oligonucleotides for qPCR and q-RT-PCR  
Pri-miR-9-2 FW 5′-GCCTGTGTGGGAAGCGAGTTG-3′ 
Pri-miR-9-2 RV 5′-GTCTTTCATTCTCACACGCTCCC-3′ 
Pri-miR-15a FW 5′-AACCTTGGAGTAAAGTAGCAGCAC-3′ 
Pri-miR-15a RV 5′-CCTTGTATTTTTGAGGCAGCAC-3′ 
Pri-miR-125b-2 FW 5′-AAGTCAGGCTCTTGGGACCT-3′ 
Pri-miR-125b-2 RV 5′-GGATGGGTCATGGTGAAAAC-3′ 
Pri-miR-132 FW 5′-TCTCCAGGGCAACCGTGGCTTTC-3′ 
Pri-miR-132 RV 5′-GCGTGGGCGTGCTGCGGGG-3′ 
Interg. Chr.4 FW 5′-TTCTGATTCTTAAAGGAGTGAC-3′ 
Interg. Chr.4 RV 5′-AATCATGCAGATAATGAC-3′ 
miR-141 FW 5'-TCCCCTGTAGCAACTGGTGAG-3' 
miR-141 RV 5'-GGAGCCATCTTTACCAGACAGTG-3' 
miR-200a FW 5'-CCCCTGTGAGCATCTTACCG-3' 
miR-200a RV 5'-CCCATCCCTGGAGTAGGAGC-3' 
FUS total FW 5'-TCAGCTAAAGCAGCTATTGACTGG-3' 
FUS total RV 5'-GCCACCACCCCGATTAAAGTCTGC-3' 
FUS endogenous FW 5'-CAGGGGTGAGCACAGACAGG-3' 
FUS endogenous RV 5'-AATAACGAGGGTAACACTGGG-3' 
FUS exon 6 FW 5'-CAGAGTGGTGGAGGTGGCAGCG-3' 
FUS exon 8 RV 5'-ACGTGATCCTTGGTCCCGAG-3' 
GAPDH FW 5'-GGAAGGTGAAGGTCGGAGTC-3' 
GAPDH RV 5'-TTACCAGAGTTAAAAGCAGCCC-3' 
U1#23 FW  5′-CAGGGGAAAGCGCGAACG-3′ 
U1#23 RV 5′-CGGCTTACCTGAAATTTTCG-3′ 
  
Oligonucleotides for Northern Blot analysis  
alfa-miR-9  5′-TCATACAGCTAGATAACCAAAGA-3′ 
alfa-miR-124  5′-GGCATTCACCGCGTGCCTTA-3′ 
alfa-miR-125b  5′-TCACAAGTTAGGGTCTCAGGGA-3′ 
alfa-miR-132  5′-UAACAGUCUACAGCCAUGGUCG-3′ 
alfa-5.8S-rRNA  5′-GTCGATGATCAATGTGTCCTG-3′ 
alfa-U1#23 5′-TGAGGCTCTGCAAAGTTCCGAA-3′ 
  
Oligonucleotides used for in vitro transcription:  
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Pri-miR-9-2 T7 Prom FW 5′-TAATACGACTCACTATAGGGCA 
AGTATCCTGGACGACCACTC-3′ 
Pri-miR-9-2 RV  5′-GCCCTCGAGAGTATTCCTGACCT 
TTCTGGT-3′ 
Pri-miR-15a T7 prom FW 5′-TAATACGACTCACTATAGGGATT 
CTTTAGGCGCGAATGTGTG-3′ 
Pri-miR-15a RV 5′-GCTATCATAAGAGCTATGAAT-3′ 
Pri-miR-125b-2 T7 prom FW 5′-TAATACGACTCACTATAGGGAG 
GTAAAAGTCTAAGTGAACC-3′ 
Pri-miR-125b-2 RV  5′-CTCCTAGGCAGAATCTATGTATG-3′ 
Pri-miR-132 T7 Prom FW 5′-TAATACGACTCACTATAGGGTG 
ACGTCAGCCCGCCCCGCGC-3′ 
Pri-miR-132 RV 5′-GTCCCCAGCCCGCGGCTCGGGG-3′ 
Pri-miR-141 T7 Prom FW 5'-TAATACGACTCACTATAGGGTA 
GCAACTGGTGAGCGCGCA-3' 
Pri-miR-141 RV 5'-TGGTCTTCAGGGCTCCCTGAAGGT-3' 
Pri-miR-143 T7 Prom FW 5′-TAATACGACTCACTATAGGGCC 
ACAGGCCACCAGAGCGGAGC-3′ 
Pri-miR-143 RV 5′-AGCACTTACCACTTCCAGGCTG-3′ 
Pri-miR-192 T7 Prom FW 5′-TAATACGACTCACTATAGGGCT 
ACCGTGGCGACGCTCCCAGGC-3′ 
Pri-miR-192 RV 5′-GGATCTCTGCTGACTGCTGGAC-3′ 
Pri-miR-199a-2 T7 Prom FW 5′-TAATACGACTCACTATAGGGG 
AGGCTTTTCCTGAGGACCGGG-3′ 
Pri-miR-199a-2 RV 5′-CAAATGTCTTCTCCTTGGAAAC-3′ 
Pri-miR-200a T7 Prom FW 5'-TAATACGACTCACTATAGGGAGC 
CCCTGCCTGCCTGGCG-3' 
pri-miR-200a RV 5'-CTCCGGATGTGCCTCGGTGG-3' 
Pri-miR-212 T7 Prom FW 5′-TAATACGACTCACTATAGGGCGG 
AGCAGCAGAGCCCCCAGC-3′ 
Pri-miR-212 RV 5′-CCTGAGGGACGGGGACTGGG-3′ 
Pri-miR-370 T7 Prom FW 5′-TAATACGACTCACTATAGGGCTCA 
TTCTACAAACCGTACAAGTC-3′ 
Pri-miR-370 RV 5′-CTGCAGCAGCGCCCGAGCTCT-3′ 
Pri-miR-513a-1 T7 Prom FW 5′-TAATACGACTCACTATAGGGGA 
GCATTTGGTCTGGGATGCCAC-3′ 
Pri-miR-513a-1 RV 5′-CTACACCCCCATCCTCAGGGAC-3′ 
Pri-miR-628 T7 Prom FW 5′-TAATACGACTCACTATAGGGCA 
TAAAGGAGCAGCACCAGAATAG-3′ 
Pri-miR-628 RV  5′-GATCAAGGTTCAAAGCACTG-3′ 
tRNA Leucine T7 PromFW 5′-TAATACGACTCACTATAGGGAG 
GACAACGGGGACAGTAA-3′ 
tRNA Leucine RV 5′-TCCACCAGAAAAACTCCAGC-3′ 
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siRNA 3'UTR of FUS/TLS (Qiagen):  
5′-AAUAACGAGGGUAACACUGGG-3′ 
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